Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
10-hydroxycamptothecin + SCH 727965
|
DCXUHYR
|
10-hydroxycamptothecin
|
Glioma (Cell Line: SF-295)
|
[2] |
|
10-hydroxycamptothecin + SCH 727965
|
DCCE56W
|
10-hydroxycamptothecin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
ABIRATERONE + SCH 727965
|
DC03JEG
|
ABIRATERONE
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
ABIRATERONE + SCH 727965
|
DCYANWA
|
ABIRATERONE
|
Glioma (Cell Line: SF-268)
|
[2] |
|
ABIRATERONE + SCH 727965
|
DCHTACI
|
ABIRATERONE
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
ABIRATERONE + SCH 727965
|
DC8PN0O
|
ABIRATERONE
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
ABIRATERONE + SCH 727965
|
DC9WBZZ
|
ABIRATERONE
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
ABIRATERONE + SCH 727965
|
DCZA38C
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
ABIRATERONE + SCH 727965
|
DCIILG5
|
ABIRATERONE
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
ABIRATERONE + SCH 727965
|
DCJH1OP
|
ABIRATERONE
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
ABT-263 + SCH 727965
|
DCAZ03L
|
ABT-263
|
Ewing sarcoma (Cell Line: TC-71)
|
[3] |
|
ABT-263 + SCH 727965
|
DCTE8D0
|
ABT-263
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[3] |
|
Acamprosate + SCH 727965
|
DC8MXHM
|
Acamprosate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Anastrozole + SCH 727965
|
DCE7CT4
|
Anastrozole
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Anastrozole + SCH 727965
|
DCU6K9C
|
Anastrozole
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[2] |
|
Anastrozole + SCH 727965
|
DC08EV3
|
Anastrozole
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Anastrozole + SCH 727965
|
DC55ULX
|
Anastrozole
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Anastrozole + SCH 727965
|
DCW4KX0
|
Anastrozole
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Anastrozole + SCH 727965
|
DCWOPDO
|
Anastrozole
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Anastrozole + SCH 727965
|
DCLHXH9
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Anastrozole + SCH 727965
|
DCUCQ4B
|
Anastrozole
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Anastrozole + SCH 727965
|
DCGYR7E
|
Anastrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[2] |
|
Anastrozole + SCH 727965
|
DCRKHMP
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[2] |
|
Anastrozole + SCH 727965
|
DCNX5Z0
|
Anastrozole
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[2] |
|
Anastrozole + SCH 727965
|
DCQLL63
|
Anastrozole
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Anastrozole + SCH 727965
|
DCLLGPZ
|
Anastrozole
|
Melanoma (Cell Line: UACC-257)
|
[2] |
|
Anastrozole + SCH 727965
|
DC1SI16
|
Anastrozole
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[2] |
|
Anastrozole + SCH 727965
|
DC7CE7O
|
Anastrozole
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Anastrozole + SCH 727965
|
DCF6OE9
|
Anastrozole
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Arfolitixorin + SCH 727965
|
DCRXCTX
|
Arfolitixorin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Arfolitixorin + SCH 727965
|
DCLQPU6
|
Arfolitixorin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Arfolitixorin + SCH 727965
|
DC42NR2
|
Arfolitixorin
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Arfolitixorin + SCH 727965
|
DCZ6SRE
|
Arfolitixorin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Armodafinil + SCH 727965
|
DC4SLL5
|
Armodafinil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Asenapine + SCH 727965
|
DCISG7Q
|
Asenapine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
AT7519 + SCH 727965
|
DCZW43S
|
AT7519
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
Azatadine + SCH 727965
|
DCY3WEV
|
Azatadine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Bafilomycin A1 + SCH 727965
|
DC5JJCS
|
Bafilomycin A1
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[2] |
|
BIO-300 + SCH 727965
|
DCVI7H4
|
BIO-300
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
BIO-300 + SCH 727965
|
DCHLWY2
|
BIO-300
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
BIO-300 + SCH 727965
|
DC9HPKT
|
BIO-300
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Bleomycin + SCH 727965
|
DCK68A0
|
Bleomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Bleomycin + SCH 727965
|
DCIDS45
|
Bleomycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Bleomycin + SCH 727965
|
DCZ15IG
|
Bleomycin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[3] |
|
Bortezomib + SCH 727965
|
DCBW8C1
|
Bortezomib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Brincidofovir + SCH 727965
|
DCF9AG3
|
Brincidofovir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
CA4P + SCH 727965
|
DC68EX1
|
CA4P
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
Cabazitaxel + SCH 727965
|
DC9S5J7
|
Cabazitaxel
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Cabazitaxel + SCH 727965
|
DCP8EM8
|
Cabazitaxel
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[2] |
|
Crizotinib + SCH 727965
|
DC8M3SZ
|
Crizotinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Crizotinib + SCH 727965
|
DCC3WDX
|
Crizotinib
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Crizotinib + SCH 727965
|
DCNOFQ3
|
Crizotinib
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Crizotinib + SCH 727965
|
DCKT5HY
|
Crizotinib
|
Melanoma (Cell Line: UACC-257)
|
[2] |
|
Crizotinib + SCH 727965
|
DC1171U
|
Crizotinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
Crizotinib + SCH 727965
|
DCUBI3M
|
Crizotinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Crizotinib + SCH 727965
|
DCGLOIU
|
Crizotinib
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Crizotinib + SCH 727965
|
DCOVHDZ
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Crizotinib + SCH 727965
|
DCKG25Q
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Cyclophosphamide + SCH 727965
|
DCPP1TD
|
Cyclophosphamide
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[2] |
|
Cyclophosphamide + SCH 727965
|
DC4XGB7
|
Cyclophosphamide
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[2] |
|
Cyclophosphamide + SCH 727965
|
DCFVBCO
|
Cyclophosphamide
|
Malignant melanoma (Cell Line: RPMI7951)
|
[2] |
|
Cyclophosphamide + SCH 727965
|
DCNZWET
|
Cyclophosphamide
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
Cyclophosphamide + SCH 727965
|
DC146CU
|
Cyclophosphamide
|
Carcinoma (Cell Line: OV90)
|
[4] |
|
Cyclophosphamide + SCH 727965
|
DCSD09J
|
Cyclophosphamide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Dacarbazine + SCH 727965
|
DCOUKFQ
|
Dacarbazine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[2] |
|
Dacarbazine + SCH 727965
|
DCA81BJ
|
Dacarbazine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Dacarbazine + SCH 727965
|
DCQ2N7Y
|
Dacarbazine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[2] |
|
Dacarbazine + SCH 727965
|
DCHM4PD
|
Dacarbazine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Dacarbazine + SCH 727965
|
DC1MAF0
|
Dacarbazine
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Dacarbazine + SCH 727965
|
DCBAIPH
|
Dacarbazine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Dacarbazine + SCH 727965
|
DCOW67D
|
Dacarbazine
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Dacarbazine + SCH 727965
|
DCSSSKZ
|
Dacarbazine
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Dacarbazine + SCH 727965
|
DCLZMEF
|
Dacarbazine
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Dacarbazine + SCH 727965
|
DCZDFYL
|
Dacarbazine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[2] |
|
Dacarbazine + SCH 727965
|
DC3R6OP
|
Dacarbazine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Dactinomycin + SCH 727965
|
DCB4EGL
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Dactinomycin + SCH 727965
|
DCDZM84
|
Dactinomycin
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Dactinomycin + SCH 727965
|
DCODE2L
|
Dactinomycin
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Dactinomycin + SCH 727965
|
DCQFK1O
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Dactinomycin + SCH 727965
|
DC4QDDX
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Dactinomycin + SCH 727965
|
DC55M2K
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Dantrolene + SCH 727965
|
DCBZP5I
|
Dantrolene
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Darunavir + SCH 727965
|
DCIJDIO
|
Darunavir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Dasatinib + SCH 727965
|
DCP08WO
|
Dasatinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[2] |
|
Dasatinib + SCH 727965
|
DCM3CEV
|
Dasatinib
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Dasatinib + SCH 727965
|
DCDNYTN
|
Dasatinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
Dasatinib + SCH 727965
|
DCEN55L
|
Dasatinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Dasatinib + SCH 727965
|
DCDK1OO
|
Dasatinib
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Dasatinib + SCH 727965
|
DCPMLYG
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Dasatinib + SCH 727965
|
DC1H6RN
|
Dasatinib
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
Dasatinib + SCH 727965
|
DC6JOAS
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[2] |
|
Dasatinib + SCH 727965
|
DCM8WNN
|
Dasatinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[2] |
|
Dasatinib + SCH 727965
|
DCP9VEV
|
Dasatinib
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Dasatinib + SCH 727965
|
DCCECJY
|
Dasatinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[2] |
|
Dasatinib + SCH 727965
|
DCA4AIV
|
Dasatinib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Dexamethasone + SCH 727965
|
DCNM3Z7
|
Dexamethasone
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[4] |
|
Dexamethasone + SCH 727965
|
DC85RYX
|
Dexamethasone
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
Dexamethasone + SCH 727965
|
DC044UG
|
Dexamethasone
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Dexamethasone + SCH 727965
|
DCUNTUC
|
Dexamethasone
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Dexamethasone + SCH 727965
|
DCJFQK7
|
Dexamethasone
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Dexamethasone + SCH 727965
|
DCDTPGA
|
Dexamethasone
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
Dexamethasone + SCH 727965
|
DCHTLOE
|
Dexamethasone
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Dexamethasone + SCH 727965
|
DC2HRX1
|
Dexamethasone
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Dexamethasone + SCH 727965
|
DCHKMNP
|
Dexamethasone
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Dexamethasone + SCH 727965
|
DCXK2VA
|
Dexamethasone
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Dexamethasone + SCH 727965
|
DC0KUZK
|
Dexamethasone
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Dexrazoxane + SCH 727965
|
DC97S69
|
Dexrazoxane
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Dexrazoxane + SCH 727965
|
DC4TJDC
|
Dexrazoxane
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Dexrazoxane + SCH 727965
|
DC92L20
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Dexrazoxane + SCH 727965
|
DCZGZUU
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Dexrazoxane + SCH 727965
|
DC0YMH3
|
Dexrazoxane
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
DFN-15 + SCH 727965
|
DCORFBU
|
DFN-15
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
DFN-15 + SCH 727965
|
DCPTSQD
|
DFN-15
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
DFN-15 + SCH 727965
|
DCCGK0M
|
DFN-15
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
DFN-15 + SCH 727965
|
DCKXTS7
|
DFN-15
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
DFN-15 + SCH 727965
|
DCCVLXE
|
DFN-15
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
DFN-15 + SCH 727965
|
DCV0TJK
|
DFN-15
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Diazoxide + SCH 727965
|
DCSHU7U
|
Diazoxide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Dichlorphenamide + SCH 727965
|
DCDAHMA
|
Dichlorphenamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Digitoxin + SCH 727965
|
DC4QCRS
|
Digitoxin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[2] |
|
Digitoxin + SCH 727965
|
DCQP3OV
|
Digitoxin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
Docetaxel + SCH 727965
|
DCQ99OW
|
Docetaxel
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Docetaxel + SCH 727965
|
DC5VSV2
|
Docetaxel
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[2] |
|
Docetaxel + SCH 727965
|
DCXAQHZ
|
Docetaxel
|
Adenocarcinoma (Cell Line: A549)
|
[2] |
|
Docetaxel + SCH 727965
|
DC7IKM8
|
Docetaxel
|
Adenocarcinoma (Cell Line: NCIH23)
|
[2] |
|
Docetaxel + SCH 727965
|
DCURJAN
|
Docetaxel
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Docetaxel + SCH 727965
|
DCAVW1C
|
Docetaxel
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
Docetaxel + SCH 727965
|
DCMJ4IR
|
Docetaxel
|
Adenocarcinoma (Cell Line: SW-620)
|
[2] |
|
Docetaxel + SCH 727965
|
DC8JR68
|
Docetaxel
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[2] |
|
Docetaxel + SCH 727965
|
DC0RTOW
|
Docetaxel
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Docetaxel + SCH 727965
|
DCU1BBK
|
Docetaxel
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Docetaxel + SCH 727965
|
DC0HSVA
|
Docetaxel
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Docetaxel + SCH 727965
|
DC0ALCE
|
Docetaxel
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[2] |
|
Docetaxel + SCH 727965
|
DCJLFSH
|
Docetaxel
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Docetaxel + SCH 727965
|
DCTOSZO
|
Docetaxel
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Docetaxel + SCH 727965
|
DCQ1WGR
|
Docetaxel
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Docetaxel + SCH 727965
|
DCIEX6G
|
Docetaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Docetaxel + SCH 727965
|
DC1G6NX
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Docetaxel + SCH 727965
|
DCAPDBS
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Docetaxel + SCH 727965
|
DCNYRPX
|
Docetaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Docetaxel + SCH 727965
|
DC2CF3A
|
Docetaxel
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Docetaxel + SCH 727965
|
DCUN8VS
|
Docetaxel
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Docetaxel + SCH 727965
|
DC9ZR80
|
Docetaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[2] |
|
Docetaxel + SCH 727965
|
DCTHI25
|
Docetaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[2] |
|
Docetaxel + SCH 727965
|
DC9QUCR
|
Docetaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[2] |
|
Docetaxel + SCH 727965
|
DCL3IVZ
|
Docetaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[2] |
|
Docetaxel + SCH 727965
|
DCIXC5E
|
Docetaxel
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[2] |
|
Docetaxel + SCH 727965
|
DCS9SWQ
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
Docetaxel + SCH 727965
|
DCOHVON
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[2] |
|
Docetaxel + SCH 727965
|
DCNG8BL
|
Docetaxel
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Docetaxel + SCH 727965
|
DCMBKDC
|
Docetaxel
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[2] |
|
Docetaxel + SCH 727965
|
DCB189C
|
Docetaxel
|
Melanoma (Cell Line: UACC-257)
|
[2] |
|
Docetaxel + SCH 727965
|
DCAEM0D
|
Docetaxel
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Docetaxel + SCH 727965
|
DC1SD9J
|
Docetaxel
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
Docetaxel + SCH 727965
|
DC2N59F
|
Docetaxel
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[2] |
|
Docetaxel + SCH 727965
|
DCAEI5S
|
Docetaxel
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Docetaxel + SCH 727965
|
DCLXB39
|
Docetaxel
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[2] |
|
Docetaxel + SCH 727965
|
DCOQA8Q
|
Docetaxel
|
Prostate carcinoma (Cell Line: PC-3)
|
[2] |
|
Docetaxel + SCH 727965
|
DCSS0Y9
|
Docetaxel
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Docetaxel + SCH 727965
|
DC3D3JO
|
Docetaxel
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Docetaxel + SCH 727965
|
DC822OJ
|
Docetaxel
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Docetaxel + SCH 727965
|
DCSUB8K
|
Docetaxel
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Dorsomorphin + SCH 727965
|
DCNT2HT
|
Dorsomorphin
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
Doxorubicin + SCH 727965
|
DCTCMNE
|
Doxorubicin
|
Adenocarcinoma (Cell Line: A427)
|
[2] |
|
Doxorubicin + SCH 727965
|
DCK3E2G
|
Doxorubicin
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[2] |
|
Doxorubicin + SCH 727965
|
DC7ID6U
|
Doxorubicin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Doxorubicin + SCH 727965
|
DC7AIX7
|
Doxorubicin
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Doxorubicin + SCH 727965
|
DCZF6WV
|
Doxorubicin
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[2] |
|
Doxorubicin + SCH 727965
|
DCSAXHR
|
Doxorubicin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
Emetine + SCH 727965
|
DC7EWGO
|
Emetine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Epirubicin + SCH 727965
|
DCK6EEZ
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Epirubicin + SCH 727965
|
DCPS529
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Epirubicin + SCH 727965
|
DCERQ1P
|
Epirubicin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Epirubicin + SCH 727965
|
DC4O45C
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Epirubicin + SCH 727965
|
DC8Y1MR
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Epirubicin + SCH 727965
|
DCR0O1K
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Epirubicin + SCH 727965
|
DCZW7U1
|
Epirubicin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Epirubicin + SCH 727965
|
DC6L4YH
|
Epirubicin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Estramustine + SCH 727965
|
DCZXSUI
|
Estramustine
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
Estramustine + SCH 727965
|
DCYZL15
|
Estramustine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[4] |
|
Estramustine + SCH 727965
|
DCSZM88
|
Estramustine
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
Estramustine + SCH 727965
|
DCQZ08X
|
Estramustine
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
Estramustine + SCH 727965
|
DCX96NX
|
Estramustine
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
Estramustine + SCH 727965
|
DCMEIR7
|
Estramustine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Estramustine + SCH 727965
|
DCYQXMH
|
Estramustine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Estramustine + SCH 727965
|
DCEDSWI
|
Estramustine
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Estramustine + SCH 727965
|
DCBJNYB
|
Estramustine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Estramustine + SCH 727965
|
DC8LG30
|
Estramustine
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
Estramustine + SCH 727965
|
DCSJ2X0
|
Estramustine
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Estramustine + SCH 727965
|
DCLA6Q6
|
Estramustine
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Estramustine + SCH 727965
|
DCFUSYF
|
Estramustine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Estramustine + SCH 727965
|
DCFHVZY
|
Estramustine
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Estramustine + SCH 727965
|
DC69O7A
|
Estramustine
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Estramustine + SCH 727965
|
DC7J14Z
|
Estramustine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Estramustine + SCH 727965
|
DC7JIS4
|
Estramustine
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Estramustine + SCH 727965
|
DCVV960
|
Estramustine
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
Estramustine + SCH 727965
|
DCWXMJA
|
Estramustine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Estramustine + SCH 727965
|
DCCYZOB
|
Estramustine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Estramustine + SCH 727965
|
DCA3GPR
|
Estramustine
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Estramustine + SCH 727965
|
DCJVNL9
|
Estramustine
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Estramustine + SCH 727965
|
DC3LHTQ
|
Estramustine
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Etomidate + SCH 727965
|
DC479IH
|
Etomidate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Etoposide + SCH 727965
|
DCAOOS0
|
Etoposide
|
Adenocarcinoma (Cell Line: CAOV3)
|
[2] |
|
Etoposide + SCH 727965
|
DC4WLKD
|
Etoposide
|
Adenocarcinoma (Cell Line: A427)
|
[2] |
|
Etoposide + SCH 727965
|
DCFVFM4
|
Etoposide
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[2] |
|
Etoposide + SCH 727965
|
DCOR5HJ
|
Etoposide
|
Adenocarcinoma (Cell Line: NCIH520)
|
[2] |
|
Etoposide + SCH 727965
|
DCP9KO3
|
Etoposide
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[2] |
|
Etoposide + SCH 727965
|
DC0X1PD
|
Etoposide
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
Etoposide + SCH 727965
|
DC5DB8D
|
Etoposide
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Etoposide + SCH 727965
|
DCPHKDC
|
Etoposide
|
Amelanotic melanoma (Cell Line: A2058)
|
[2] |
|
Etoposide + SCH 727965
|
DC9SCOV
|
Etoposide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[2] |
|
Etoposide + SCH 727965
|
DC2T2PJ
|
Etoposide
|
Malignant melanoma (Cell Line: RPMI7951)
|
[2] |
|
Etoposide + SCH 727965
|
DCLQVXA
|
Etoposide
|
Malignant melanoma (Cell Line: SKMEL30)
|
[2] |
|
Etoposide + SCH 727965
|
DC2MDCN
|
Etoposide
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[2] |
|
Etoposide + SCH 727965
|
DCVW22R
|
Etoposide
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
Etoposide + SCH 727965
|
DCCIXZ5
|
Etoposide
|
Prostate carcinoma (Cell Line: LNCAP)
|
[2] |
|
Etoposide + SCH 727965
|
DCAP27V
|
Etoposide
|
Prostate carcinoma (Cell Line: VCAP)
|
[2] |
|
Etoposide + SCH 727965
|
DCXJFJL
|
Etoposide
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
Etoposide + SCH 727965
|
DCT7JX6
|
Etoposide
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
Etoposide + SCH 727965
|
DC0BLPN
|
Etoposide
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[4] |
|
Evacetrapib + SCH 727965
|
DCR4X1T
|
Evacetrapib
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[2] |
|
Exherin + SCH 727965
|
DC8YYKC
|
Exherin
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
Ezetimibe + SCH 727965
|
DCK0XI2
|
Ezetimibe
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Fludarabine + SCH 727965
|
DC1BWWZ
|
Fludarabine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Fluorouracil + SCH 727965
|
DCDBYUC
|
Fluorouracil
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
Fluorouracil + SCH 727965
|
DCBU8L8
|
Fluorouracil
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[4] |
|
Fluorouracil + SCH 727965
|
DC1S8V2
|
Fluorouracil
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
Fluorouracil + SCH 727965
|
DCMXOVM
|
Fluorouracil
|
Breast carcinoma (Cell Line: ZR751)
|
[4] |
|
Fluorouracil + SCH 727965
|
DC09CDH
|
Fluorouracil
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
Fluorouracil + SCH 727965
|
DC48PJC
|
Fluorouracil
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
Fluorouracil + SCH 727965
|
DCH3H6P
|
Fluorouracil
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
Fluorouracil + SCH 727965
|
DCL8X1Q
|
Fluorouracil
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Fluorouracil + SCH 727965
|
DCYUJLJ
|
Fluorouracil
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCRNCMM
|
Fluorouracil
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
Fluorouracil + SCH 727965
|
DC831GZ
|
Fluorouracil
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCI7RXL
|
Fluorouracil
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
Fluorouracil + SCH 727965
|
DC0X9WM
|
Fluorouracil
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCG6BQX
|
Fluorouracil
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCK3AOJ
|
Fluorouracil
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCQK8AH
|
Fluorouracil
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCWQKGT
|
Fluorouracil
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCSMIZR
|
Fluorouracil
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Fluorouracil + SCH 727965
|
DC04700
|
Fluorouracil
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCPTEVM
|
Fluorouracil
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCIKPVF
|
Fluorouracil
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Fluorouracil + SCH 727965
|
DC569MT
|
Fluorouracil
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
Fluorouracil + SCH 727965
|
DC9IR3D
|
Fluorouracil
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCUWABS
|
Fluorouracil
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Fluorouracil + SCH 727965
|
DC6YH9L
|
Fluorouracil
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Fluorouracil + SCH 727965
|
DC1L5UZ
|
Fluorouracil
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCRP1YB
|
Fluorouracil
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCBSK0K
|
Fluorouracil
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCTC3K1
|
Fluorouracil
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Fluorouracil + SCH 727965
|
DCZ3H5M
|
Fluorouracil
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
GDC-0084 + SCH 727965
|
DC4ROEY
|
GDC-0084
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[3] |
|
Gefitinib + SCH 727965
|
DC8XHCY
|
Gefitinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Gefitinib + SCH 727965
|
DCWJHOH
|
Gefitinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[2] |
|
Gefitinib + SCH 727965
|
DCH7U1T
|
Gefitinib
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Gefitinib + SCH 727965
|
DCRKGEK
|
Gefitinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Gefitinib + SCH 727965
|
DCFFHUQ
|
Gefitinib
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Gefitinib + SCH 727965
|
DC72GHP
|
Gefitinib
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Gefitinib + SCH 727965
|
DCYYI8L
|
Gefitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Gefitinib + SCH 727965
|
DCJDQ21
|
Gefitinib
|
Melanoma (Cell Line: UACC-257)
|
[2] |
|
Gefitinib + SCH 727965
|
DCT8XBL
|
Gefitinib
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Gefitinib + SCH 727965
|
DCSGCJY
|
Gefitinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Gefitinib + SCH 727965
|
DCBGK7G
|
Gefitinib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Gefitinib + SCH 727965
|
DC5DTTN
|
Gefitinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Gemcitabine + SCH 727965
|
DC8G2TR
|
Gemcitabine
|
Adenocarcinoma (Cell Line: CAOV3)
|
[2] |
|
Gemcitabine + SCH 727965
|
DCV8BP8
|
Gemcitabine
|
Adenocarcinoma (Cell Line: A427)
|
[2] |
|
Gemcitabine + SCH 727965
|
DCENKJY
|
Gemcitabine
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[2] |
|
Gemcitabine + SCH 727965
|
DC4O12U
|
Gemcitabine
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Gemcitabine + SCH 727965
|
DCIAKW1
|
Gemcitabine
|
Adenocarcinoma (Cell Line: SW-620)
|
[2] |
|
Gemcitabine + SCH 727965
|
DC3SIAH
|
Gemcitabine
|
Amelanotic melanoma (Cell Line: A2058)
|
[2] |
|
Gemcitabine + SCH 727965
|
DCCD42H
|
Gemcitabine
|
Germ cell tumour (Cell Line: PA1)
|
[2] |
|
Gemcitabine + SCH 727965
|
DC2J54O
|
Gemcitabine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[2] |
|
Gemcitabine + SCH 727965
|
DC2OECQ
|
Gemcitabine
|
Malignant melanoma (Cell Line: HT144)
|
[2] |
|
Gemcitabine + SCH 727965
|
DC18VO9
|
Gemcitabine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[2] |
|
Gemcitabine + SCH 727965
|
DCQB3UW
|
Gemcitabine
|
Malignant melanoma (Cell Line: SKMEL30)
|
[2] |
|
Gemcitabine + SCH 727965
|
DCVAHN6
|
Gemcitabine
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Gemcitabine + SCH 727965
|
DC5J4Q9
|
Gemcitabine
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
Gemcitabine + SCH 727965
|
DCMWEZ8
|
Gemcitabine
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
Hepzato + SCH 727965
|
DC12Y5W
|
Hepzato
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Hepzato + SCH 727965
|
DCYWM1H
|
Hepzato
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Hyodeoxycholic acid + SCH 727965
|
DCEEE09
|
Hyodeoxycholic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Idarubicin + SCH 727965
|
DCOT79P
|
Idarubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Imatinib + SCH 727965
|
DCT0BSR
|
Imatinib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Imatinib + SCH 727965
|
DCK244C
|
Imatinib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Indazole derivative 5 + SCH 727965
|
DCVZ3BN
|
Indazole derivative 5
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Indazole derivative 5 + SCH 727965
|
DC7BSTO
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + SCH 727965
|
DCGJB50
|
Indazole derivative 5
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + SCH 727965
|
DCTL4QT
|
Indazole derivative 5
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
JNK-IN-8 + SCH 727965
|
DC8ROPX
|
JNK-IN-8
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Lapatinib + SCH 727965
|
DCN6P3D
|
Lapatinib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Lapatinib + SCH 727965
|
DCQM0BR
|
Lapatinib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Lapatinib + SCH 727965
|
DCXAHNE
|
Lapatinib
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Lenalidomide + SCH 727965
|
DCUM7RX
|
Lenalidomide
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Lenalidomide + SCH 727965
|
DCJUHQ2
|
Lenalidomide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Lenalidomide + SCH 727965
|
DC4BQVM
|
Lenalidomide
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Lenalidomide + SCH 727965
|
DCSJKKL
|
Lenalidomide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Lenalidomide + SCH 727965
|
DC22SL8
|
Lenalidomide
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Lenalidomide + SCH 727965
|
DC5NWBP
|
Lenalidomide
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Lenalidomide + SCH 727965
|
DCE5F5D
|
Lenalidomide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Lenalidomide + SCH 727965
|
DC1Y8RB
|
Lenalidomide
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Levamisole + SCH 727965
|
DCS7HOU
|
Levamisole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
LIAROZOLE + SCH 727965
|
DCQE6YY
|
LIAROZOLE
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
LIAROZOLE + SCH 727965
|
DC7MZHH
|
LIAROZOLE
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
LIAROZOLE + SCH 727965
|
DCBXL1M
|
LIAROZOLE
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
LIAROZOLE + SCH 727965
|
DC7KCFB
|
LIAROZOLE
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
LY2523355 + SCH 727965
|
DCY5MEJ
|
LY2523355
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
LY2874455 + SCH 727965
|
DCEJHBP
|
LY2874455
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
Mecamylamine + SCH 727965
|
DCRZNEZ
|
Mecamylamine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Mechlorethamine + SCH 727965
|
DCQOJIT
|
Mechlorethamine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Mechlorethamine + SCH 727965
|
DC4G4UG
|
Mechlorethamine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Mechlorethamine + SCH 727965
|
DCFZWV6
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Mechlorethamine + SCH 727965
|
DC4J9T9
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Metaxalone + SCH 727965
|
DCUUVS9
|
Metaxalone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Metformin + SCH 727965
|
DCXI6UM
|
Metformin
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[2] |
|
Metformin + SCH 727965
|
DCWMK6B
|
Metformin
|
Adenocarcinoma (Cell Line: NCIH520)
|
[2] |
|
Metformin + SCH 727965
|
DCAJO7N
|
Metformin
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Metformin + SCH 727965
|
DCJNORO
|
Metformin
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
Metformin + SCH 727965
|
DCAPSCC
|
Metformin
|
Malignant melanoma (Cell Line: RPMI7951)
|
[2] |
|
Metformin + SCH 727965
|
DC97D1X
|
Metformin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
Metformin + SCH 727965
|
DCZC4LL
|
Metformin
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
Metformin + SCH 727965
|
DCKCT4P
|
Metformin
|
Carcinoma (Cell Line: OV90)
|
[4] |
|
Metformin + SCH 727965
|
DCDLBW8
|
Metformin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Methotrexate + SCH 727965
|
DCJ4YRG
|
Methotrexate
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[2] |
|
Methotrexate + SCH 727965
|
DCN6B2L
|
Methotrexate
|
Germ cell tumour (Cell Line: PA1)
|
[2] |
|
Methotrexate + SCH 727965
|
DC2ZPNQ
|
Methotrexate
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
Methotrexate + SCH 727965
|
DCZEAQA
|
Methotrexate
|
Carcinoma (Cell Line: EFM192B)
|
[4] |
|
Methotrexate + SCH 727965
|
DC9GQ7B
|
Methotrexate
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
Methylene blue + SCH 727965
|
DC6MVM9
|
Methylene blue
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Mitomycin + SCH 727965
|
DCS0GM9
|
Mitomycin
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
Mitomycin + SCH 727965
|
DC4HDUC
|
Mitomycin
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
Mitomycin + SCH 727965
|
DCUWVQD
|
Mitomycin
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
Mitomycin + SCH 727965
|
DCNZ0YD
|
Mitomycin
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
Mitomycin + SCH 727965
|
DCXFKLD
|
Mitomycin
|
Carcinoma (Cell Line: EFM192B)
|
[4] |
|
Mitomycin + SCH 727965
|
DCJ3BAG
|
Mitomycin
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
Mitomycin + SCH 727965
|
DCEYV7Z
|
Mitomycin
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Mitomycin + SCH 727965
|
DCG93NK
|
Mitomycin
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
Mitomycin + SCH 727965
|
DCSM2M7
|
Mitomycin
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
Mitomycin + SCH 727965
|
DCCJBS9
|
Mitomycin
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Mitomycin + SCH 727965
|
DCI5X3U
|
Mitomycin
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Mitomycin + SCH 727965
|
DCHW4K6
|
Mitomycin
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
Mitomycin + SCH 727965
|
DCYC2JR
|
Mitomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Mitomycin + SCH 727965
|
DCGCYU4
|
Mitomycin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Mitomycin + SCH 727965
|
DC0410N
|
Mitomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Mitomycin + SCH 727965
|
DCOHRQV
|
Mitomycin
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Mitomycin + SCH 727965
|
DCNH1Z8
|
Mitomycin
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Mitomycin + SCH 727965
|
DCPB27R
|
Mitomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Mitomycin + SCH 727965
|
DC5UFGA
|
Mitomycin
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Mitomycin + SCH 727965
|
DC1SP1I
|
Mitomycin
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Mitomycin + SCH 727965
|
DCOQ9MX
|
Mitomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Mitomycin + SCH 727965
|
DC0CSC5
|
Mitomycin
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Mitomycin + SCH 727965
|
DCWOYSC
|
Mitomycin
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Mitomycin + SCH 727965
|
DC96PIK
|
Mitomycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Mitomycin + SCH 727965
|
DCJOLNN
|
Mitomycin
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
MK-2206 + SCH 727965
|
DCWDGTF
|
MK-2206
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
NVP-AUY922 + SCH 727965
|
DCU4FCV
|
NVP-AUY922
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
NVP-AUY922 + SCH 727965
|
DC3HLYS
|
NVP-AUY922
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
Oxandrolone + SCH 727965
|
DCYCYI9
|
Oxandrolone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Pelitinib + SCH 727965
|
DCMJ4VA
|
Pelitinib
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
Pentamidine + SCH 727965
|
DCMJPJW
|
Pentamidine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Pepstatin + SCH 727965
|
DCIZHTM
|
Pepstatin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Picoplatin + SCH 727965
|
DC9T9IU
|
Picoplatin
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Picoplatin + SCH 727965
|
DCV2428
|
Picoplatin
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
Picoplatin + SCH 727965
|
DCFP548
|
Picoplatin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Picoplatin + SCH 727965
|
DCCZVZ5
|
Picoplatin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Picoplatin + SCH 727965
|
DCC1NRT
|
Picoplatin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Picoplatin + SCH 727965
|
DC720PE
|
Picoplatin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Picoplatin + SCH 727965
|
DCR2ESQ
|
Picoplatin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Picoplatin + SCH 727965
|
DCSP3L4
|
Picoplatin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Picoplatin + SCH 727965
|
DC5N9FC
|
Picoplatin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCH2MW4
|
PMID28460551-Compound-2
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC8OXX1
|
PMID28460551-Compound-2
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC3QFQU
|
PMID28460551-Compound-2
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[4] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC4B27N
|
PMID28460551-Compound-2
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCZRF6F
|
PMID28460551-Compound-2
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC8YQ64
|
PMID28460551-Compound-2
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCW5359
|
PMID28460551-Compound-2
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCBOULC
|
PMID28460551-Compound-2
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCXIFSU
|
PMID28460551-Compound-2
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC07T4H
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCL7LAS
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCG7ISF
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC0241Q
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCOM2CA
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC6946P
|
PMID28460551-Compound-2
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCAMXSP
|
PMID28460551-Compound-2
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DCHXSGR
|
PMID28460551-Compound-2
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC85SEE
|
PMID28460551-Compound-2
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC38TFX
|
PMID28460551-Compound-2
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
PMID28460551-Compound-2 + SCH 727965
|
DC57ZSV
|
PMID28460551-Compound-2
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Pyrazinamide + SCH 727965
|
DC2C8MT
|
Pyrazinamide
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[2] |
|
Raloxifene + SCH 727965
|
DCHAV8B
|
Raloxifene
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + SCH 727965
|
DCQCVBT
|
Raloxifene
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Raloxifene + SCH 727965
|
DC9VJH2
|
Raloxifene
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + SCH 727965
|
DCQN83C
|
Raloxifene
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + SCH 727965
|
DCAF86N
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + SCH 727965
|
DCEZP9H
|
Raloxifene
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + SCH 727965
|
DCHA4GC
|
Raloxifene
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Raloxifene + SCH 727965
|
DC4MA4U
|
Raloxifene
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Raloxifene + SCH 727965
|
DCIMAS1
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Raloxifene + SCH 727965
|
DCFE127
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Raloxifene + SCH 727965
|
DCQXSQ5
|
Raloxifene
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Raloxifene + SCH 727965
|
DCRXJSM
|
Raloxifene
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Raloxifene + SCH 727965
|
DC8ZMXU
|
Raloxifene
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Raloxifene + SCH 727965
|
DC61X86
|
Raloxifene
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Raloxifene + SCH 727965
|
DCR9X3C
|
Raloxifene
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Romidepsin + SCH 727965
|
DC8EFM9
|
Romidepsin
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
Romidepsin + SCH 727965
|
DCC3BL0
|
Romidepsin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Ruxolitinib + SCH 727965
|
DCDBXVA
|
Ruxolitinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Ruxolitinib + SCH 727965
|
DCPD9RD
|
Ruxolitinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Ruxolitinib + SCH 727965
|
DC9YTRL
|
Ruxolitinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Ruxolitinib + SCH 727965
|
DCUOLNB
|
Ruxolitinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Ruxolitinib + SCH 727965
|
DCHXZPU
|
Ruxolitinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Ruxolitinib + SCH 727965
|
DCADPC5
|
Ruxolitinib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Ruxolitinib + SCH 727965
|
DCWXNBI
|
Ruxolitinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Sapanisertib + SCH 727965
|
DCQWO4H
|
Sapanisertib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[3] |
|
SCH 727965 + Aprepitant
|
DCLVVJ2
|
Aprepitant
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Meclofenamic acid
|
DCTGMPR
|
Meclofenamic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Mebutamate
|
DCG9CYR
|
Mebutamate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Fulvestrant
|
DCICTVU
|
Fulvestrant
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
SCH 727965 + Fulvestrant
|
DCZ0200
|
Fulvestrant
|
Glioma (Cell Line: SF-268)
|
[2] |
|
SCH 727965 + Fulvestrant
|
DCLDDXZ
|
Fulvestrant
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
SCH 727965 + Gefitinib
|
DCOO1RZ
|
Gefitinib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Gefitinib
|
DCA6DQ1
|
Gefitinib
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
SCH 727965 + PD-0325901
|
DCRDCBN
|
PD-0325901
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
SCH 727965 + PD-0325901
|
DCPJ3K3
|
PD-0325901
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + AT13387
|
DCOULIA
|
AT13387
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[2] |
|
SCH 727965 + Kanamycin
|
DCAQGOP
|
Kanamycin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Citalopram
|
DC02FFI
|
Citalopram
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Imipramine
|
DCUQR3J
|
Imipramine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Ixabepilone
|
DCNR31D
|
Ixabepilone
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SCH 727965 + Ixabepilone
|
DCUNFBK
|
Ixabepilone
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
SCH 727965 + PF-3758309
|
DCG3M3L
|
PF-3758309
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
SCH 727965 + Lapatinib
|
DCQRP13
|
Lapatinib
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + Artemether
|
DCCQ10Q
|
Artemether
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
SCH 727965 + Cyclophosphamide
|
DCMG1QU
|
Cyclophosphamide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SCH 727965 + Isoniazid
|
DCTH1LK
|
Isoniazid
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
SCH 727965 + Mephenytoin
|
DCMZXUV
|
Mephenytoin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + RTB101
|
DCVRVAO
|
RTB101
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + SCH-900776
|
DCTFAHC
|
SCH-900776
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + Anamorelin
|
DCETO9M
|
Anamorelin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Alvespimycin hydrochloride
|
DCLAQA8
|
Alvespimycin hydrochloride
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[2] |
|
SCH 727965 + Fomepizole
|
DCEKY8Z
|
Fomepizole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Plicamycin
|
DCODDKT
|
Plicamycin
|
Glioma (Cell Line: SF-295)
|
[2] |
|
SCH 727965 + Plicamycin
|
DCWFVW1
|
Plicamycin
|
Glioma (Cell Line: SF-268)
|
[2] |
|
SCH 727965 + Plicamycin
|
DC0YANM
|
Plicamycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
SCH 727965 + Triapine
|
DCPNE7X
|
Triapine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Triapine
|
DCQ0X6B
|
Triapine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
SCH 727965 + Dexmedetomidine
|
DCF59TD
|
Dexmedetomidine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCIKU5O
|
10-hydroxycamptothecin
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + Dronedarone
|
DCIQCPL
|
Dronedarone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Pralatrexate
|
DC92THY
|
Pralatrexate
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SCH 727965 + Pralatrexate
|
DCV86GJ
|
Pralatrexate
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
SCH 727965 + Pralatrexate
|
DCE9E4W
|
Pralatrexate
|
Glioma (Cell Line: SF-295)
|
[2] |
|
SCH 727965 + IT-141
|
DCZX4UN
|
IT-141
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + SNX-2112
|
DCV8855
|
SNX-2112
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + BHV-0223
|
DCLX0Z9
|
BHV-0223
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Terameprocol
|
DC7RJH6
|
Terameprocol
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
SCH 727965 + Terameprocol
|
DCOYWKC
|
Terameprocol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Terameprocol
|
DC2Y8P6
|
Terameprocol
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
SCH 727965 + Terameprocol
|
DCF38PO
|
Terameprocol
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
SCH 727965 + Terameprocol
|
DCDI8OK
|
Terameprocol
|
Glioma (Cell Line: SF-295)
|
[2] |
|
SCH 727965 + Terameprocol
|
DCGOUB7
|
Terameprocol
|
Glioma (Cell Line: SF-268)
|
[2] |
|
SCH 727965 + Guanfacine
|
DC7RZCN
|
Guanfacine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Amodiaquine
|
DCHMDHU
|
Amodiaquine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Erlotinib
|
DCOO2Y4
|
Erlotinib
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + Docetaxel
|
DCIVDY9
|
Docetaxel
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
SCH 727965 + SNS-032
|
DCOENNU
|
SNS-032
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
SCH 727965 + GDC-0980/RG7422
|
DC6SUCL
|
GDC-0980/RG7422
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
SCH 727965 + Phensuximide
|
DCFETI2
|
Phensuximide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + MK-5108
|
DCHYKG3
|
MK-5108
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
SCH 727965 + MK-5108
|
DCCWBWD
|
MK-5108
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + Bendamustine hydrochloride
|
DC5RF1I
|
Bendamustine hydrochloride
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
SCH 727965 + PHA-739358
|
DC1P13M
|
PHA-739358
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Mitomycin
|
DCH9LDW
|
Mitomycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SCH 727965 + Clopidogrel
|
DC86TDM
|
Clopidogrel
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Pentamidine
|
DC8G3IV
|
Pentamidine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Vincristine
|
DCK1VXN
|
Vincristine
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[2] |
|
SCH 727965 + Triflupromazine
|
DC6K7GW
|
Triflupromazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + PF-02545920
|
DCO6XF4
|
PF-02545920
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + AS602868
|
DC1BFOC
|
AS602868
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
SCH 727965 + GINKGOLIDE A
|
DC9TQUL
|
GINKGOLIDE A
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Tamoxifen
|
DCIQOY6
|
Tamoxifen
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
SCH 727965 + Ridaforolimus
|
DC0BICP
|
Ridaforolimus
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + TEM
|
DCEB8VI
|
TEM
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
SCH 727965 + MK-4827
|
DCO7WUL
|
MK-4827
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + ABT-263
|
DC23P0A
|
ABT-263
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
SCH 727965 + Bortezomib
|
DC8GWAA
|
Bortezomib
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + Mesalazine
|
DCC8I0G
|
Mesalazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Valrubicin
|
DC3ECH3
|
Valrubicin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SCH 727965 + Valrubicin
|
DC0CBU4
|
Valrubicin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
SCH 727965 + Valrubicin
|
DCC1JXJ
|
Valrubicin
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
SCH 727965 + Valrubicin
|
DC2Z4XG
|
Valrubicin
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
SCH 727965 + Valrubicin
|
DC7IJ0V
|
Valrubicin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
SCH 727965 + Valrubicin
|
DCPXMZ9
|
Valrubicin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
SCH 727965 + Valrubicin
|
DC4QHED
|
Valrubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
SCH 727965 + Valrubicin
|
DCM1H33
|
Valrubicin
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
SCH 727965 + Valrubicin
|
DCCXNR5
|
Valrubicin
|
Glioma (Cell Line: SF-539)
|
[2] |
|
SCH 727965 + Valrubicin
|
DC74M4D
|
Valrubicin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
SCH 727965 + Valrubicin
|
DC7AHQP
|
Valrubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
SCH 727965 + Valrubicin
|
DC52B8U
|
Valrubicin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
SCH 727965 + Valrubicin
|
DCZSYQ0
|
Valrubicin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
SCH 727965 + BIIB-021
|
DC3WRRS
|
BIIB-021
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
SCH 727965 + BMS-754807
|
DC9SBLG
|
BMS-754807
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
SCH 727965 + Trimethobenzamide
|
DCEQ2J6
|
Trimethobenzamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Maprotiline
|
DC3F6HG
|
Maprotiline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Leflunomide
|
DCDAXOI
|
Leflunomide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Theophylline
|
DCXLKYH
|
Theophylline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Chlorambucil
|
DCS7XAD
|
Chlorambucil
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
SCH 727965 + Brincidofovir
|
DC2HEMH
|
Brincidofovir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Sorafenib
|
DCZE5D5
|
Sorafenib
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + ER819762
|
DCZUPN5
|
ER819762
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
SCH 727965 + ER819762
|
DCRS8Z5
|
ER819762
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
SCH 727965 + Asenapine
|
DCPORRP
|
Asenapine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + MK-2206
|
DCMRY0I
|
MK-2206
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + Pomalidomide
|
DCUVXGK
|
Pomalidomide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Pomalidomide
|
DCUJ8PG
|
Pomalidomide
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
SCH 727965 + Pomalidomide
|
DCRAJ9Q
|
Pomalidomide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
SCH 727965 + Vinflunine
|
DCZMQQG
|
Vinflunine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SCH 727965 + Vinflunine
|
DCU1IQH
|
Vinflunine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SCH 727965 + Vinflunine
|
DCXRM9O
|
Vinflunine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
SCH 727965 + Vinflunine
|
DCSPKNB
|
Vinflunine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
SCH 727965 + Vinflunine
|
DCN5DWM
|
Vinflunine
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
SCH 727965 + Vinflunine
|
DCR68GN
|
Vinflunine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
SCH 727965 + Mercaptopurine
|
DCLTBV5
|
Mercaptopurine
|
Glioma (Cell Line: SF-295)
|
[2] |
|
SCH 727965 + Endoxifen
|
DCLVHUM
|
Endoxifen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + CYTISINE
|
DCM1EIT
|
CYTISINE
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
SCH 727965 + CPG 52364
|
DCKEPJA
|
CPG 52364
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
SCH 727965 + Silver sulfadiazine
|
DCDZG0E
|
Silver sulfadiazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + PMID28870136-Compound-43
|
DCRJJ10
|
PMID28870136-Compound-43
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
SCH 727965 + PMID28870136-Compound-43
|
DC5UH2Y
|
PMID28870136-Compound-43
|
Glioma (Cell Line: SF-295)
|
[2] |
|
SCH 727965 + FORMESTANE
|
DCQ0SM4
|
FORMESTANE
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Vorinostat
|
DCPWG1I
|
Vorinostat
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Aminolevulinic Acid Hydrochloride
|
DC7Y3VC
|
Aminolevulinic Acid Hydrochloride
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SCH 727965 + Aminolevulinic Acid Hydrochloride
|
DCCIOMO
|
Aminolevulinic Acid Hydrochloride
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
SCH 727965 + Aminolevulinic Acid Hydrochloride
|
DCCTON2
|
Aminolevulinic Acid Hydrochloride
|
Glioma (Cell Line: SF-268)
|
[2] |
|
SCH 727965 + Cerivastatin
|
DC9F4RA
|
Cerivastatin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Dasatinib
|
DCJC7I1
|
Dasatinib
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[2] |
|
SCH 727965 + Dasatinib
|
DCWNMXN
|
Dasatinib
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
SCH 727965 + L-165041
|
DCRF3RC
|
L-165041
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SCH 727965 + Pentostatin
|
DCVW99F
|
Pentostatin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
SCH 727965 + Fulvestrant
|
DCHVDZN
|
Fulvestrant
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
SCH 727965 + PD-0325901
|
DCIYVNH
|
PD-0325901
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[4] |
|
SCH 727965 + PD-0325901
|
DC8NACR
|
PD-0325901
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
SCH 727965 + PD-0325901
|
DC12B2O
|
PD-0325901
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
SCH 727965 + PD-0325901
|
DCGQ8SN
|
PD-0325901
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + PD-0325901
|
DCGQFR4
|
PD-0325901
|
Carcinoma (Cell Line: EFM192B)
|
[4] |
|
SCH 727965 + PD-0325901
|
DCTFVFK
|
PD-0325901
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
SCH 727965 + PD-0325901
|
DC0SVTA
|
PD-0325901
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
SCH 727965 + PD-0325901
|
DC3QN74
|
PD-0325901
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
SCH 727965 + Ixabepilone
|
DCIR0UF
|
Ixabepilone
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
SCH 727965 + Lapatinib
|
DCQLMYB
|
Lapatinib
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[4] |
|
SCH 727965 + Lapatinib
|
DC4T2R3
|
Lapatinib
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
SCH 727965 + Lapatinib
|
DCM6MY8
|
Lapatinib
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
SCH 727965 + Lapatinib
|
DCHMXVX
|
Lapatinib
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + Lapatinib
|
DCBHIQZ
|
Lapatinib
|
Carcinoma (Cell Line: OV90)
|
[4] |
|
SCH 727965 + Lapatinib
|
DCRJQLH
|
Lapatinib
|
Carcinoma (Cell Line: EFM192B)
|
[4] |
|
SCH 727965 + Lapatinib
|
DCW8CRT
|
Lapatinib
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
SCH 727965 + Lapatinib
|
DC5WHWD
|
Lapatinib
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
SCH 727965 + Lapatinib
|
DC8FPFW
|
Lapatinib
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
SCH 727965 + Lapatinib
|
DCDP1Q8
|
Lapatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
SCH 727965 + Lapatinib
|
DCBIRCZ
|
Lapatinib
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[4] |
|
SCH 727965 + MK-1775
|
DCG2B84
|
MK-1775
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + MK-1775
|
DC7BFLH
|
MK-1775
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
SCH 727965 + MK-1775
|
DCZ6Z2X
|
MK-1775
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
SCH 727965 + RTB101
|
DC6OAUB
|
RTB101
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[4] |
|
SCH 727965 + RTB101
|
DC9YP2G
|
RTB101
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
SCH 727965 + RTB101
|
DC932MB
|
RTB101
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
SCH 727965 + RTB101
|
DCE2309
|
RTB101
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + RTB101
|
DCZPD8J
|
RTB101
|
Carcinoma (Cell Line: EFM192B)
|
[4] |
|
SCH 727965 + RTB101
|
DCUI5MH
|
RTB101
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
SCH 727965 + RTB101
|
DC1G1GT
|
RTB101
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
SCH 727965 + RTB101
|
DCFWUUJ
|
RTB101
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
SCH 727965 + RTB101
|
DCIYXJ2
|
RTB101
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[4] |
|
SCH 727965 + SCH-900776
|
DC9Z8IP
|
SCH-900776
|
Carcinoma (Cell Line: OV90)
|
[4] |
|
SCH 727965 + SCH-900776
|
DCYGQRW
|
SCH-900776
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
SCH 727965 + SCH-900776
|
DC7U843
|
SCH-900776
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
SCH 727965 + SCH-900776
|
DCLL6ON
|
SCH-900776
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
SCH 727965 + Plicamycin
|
DCMAAYH
|
Plicamycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
SCH 727965 + Triapine
|
DCMTEWP
|
Triapine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCS7S2U
|
10-hydroxycamptothecin
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCL7Y0G
|
10-hydroxycamptothecin
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DC5ECRN
|
10-hydroxycamptothecin
|
Carcinoma (Cell Line: EFM192B)
|
[4] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCQB9JS
|
10-hydroxycamptothecin
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DC1GXW1
|
10-hydroxycamptothecin
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
SCH 727965 + SNX-2112
|
DCVMJQ6
|
SNX-2112
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[4] |
|
SCH 727965 + SNX-2112
|
DCBAY93
|
SNX-2112
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + SNX-2112
|
DCMBCYK
|
SNX-2112
|
Carcinoma (Cell Line: EFM192B)
|
[4] |
|
SCH 727965 + SNX-2112
|
DCFZ852
|
SNX-2112
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
SCH 727965 + SNX-2112
|
DCUJXOJ
|
SNX-2112
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
SCH 727965 + SNX-2112
|
DC3VM0G
|
SNX-2112
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
SCH 727965 + SNX-2112
|
DC5UA49
|
SNX-2112
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
SCH 727965 + SNX-2112
|
DCSP8J2
|
SNX-2112
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[4] |
|
SCH 727965 + Terameprocol
|
DCMLU56
|
Terameprocol
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
SCH 727965 + Erlotinib
|
DC06VGB
|
Erlotinib
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[4] |
|
SCH 727965 + Erlotinib
|
DC93LHY
|
Erlotinib
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
SCH 727965 + Erlotinib
|
DCEDSJE
|
Erlotinib
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
SCH 727965 + Erlotinib
|
DCUBHQ4
|
Erlotinib
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + Erlotinib
|
DCFGRDD
|
Erlotinib
|
Carcinoma (Cell Line: OV90)
|
[4] |
|
SCH 727965 + Erlotinib
|
DCR1TJX
|
Erlotinib
|
Carcinoma (Cell Line: EFM192B)
|
[4] |
|
SCH 727965 + Erlotinib
|
DCTVIH3
|
Erlotinib
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
SCH 727965 + Erlotinib
|
DCA0IUH
|
Erlotinib
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
SCH 727965 + Erlotinib
|
DC17L6R
|
Erlotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
SCH 727965 + Erlotinib
|
DCKS52X
|
Erlotinib
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[4] |
|
SCH 727965 + Ifosfamide
|
DC5HO05
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
SCH 727965 + MK-5108
|
DC1J31K
|
MK-5108
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
SCH 727965 + Ridaforolimus
|
DCQ2OYW
|
Ridaforolimus
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[4] |
|
SCH 727965 + Ridaforolimus
|
DC72FKC
|
Ridaforolimus
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
SCH 727965 + Ridaforolimus
|
DCNDLIW
|
Ridaforolimus
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
SCH 727965 + Ridaforolimus
|
DCGKR47
|
Ridaforolimus
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + Ridaforolimus
|
DCXC8ZA
|
Ridaforolimus
|
Carcinoma (Cell Line: EFM192B)
|
[4] |
|
SCH 727965 + Ridaforolimus
|
DCFEANK
|
Ridaforolimus
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
SCH 727965 + Ridaforolimus
|
DCH9K1D
|
Ridaforolimus
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
SCH 727965 + Ridaforolimus
|
DC14K0D
|
Ridaforolimus
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
SCH 727965 + Ridaforolimus
|
DCGD6X4
|
Ridaforolimus
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[4] |
|
SCH 727965 + TEM
|
DCN6ED9
|
TEM
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
SCH 727965 + TEM
|
DCVS7TD
|
TEM
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
SCH 727965 + MK-4827
|
DC7N05K
|
MK-4827
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[4] |
|
SCH 727965 + MK-4827
|
DCLGDG3
|
MK-4827
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
SCH 727965 + MK-4827
|
DCNWV2J
|
MK-4827
|
Breast carcinoma (Cell Line: ZR751)
|
[4] |
|
SCH 727965 + MK-4827
|
DCA24FU
|
MK-4827
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
SCH 727965 + MK-4827
|
DC697WH
|
MK-4827
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + MK-4827
|
DC0HB0P
|
MK-4827
|
Carcinoma (Cell Line: EFM192B)
|
[4] |
|
SCH 727965 + MK-4827
|
DCW1ILJ
|
MK-4827
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
SCH 727965 + MK-4827
|
DCMZKFN
|
MK-4827
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
SCH 727965 + MK-4827
|
DCXSUXF
|
MK-4827
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
SCH 727965 + MK-4827
|
DCEGW23
|
MK-4827
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
SCH 727965 + Idarubicin
|
DC80MMZ
|
Idarubicin
|
Carcinoma (Cell Line: OV90)
|
[4] |
|
SCH 727965 + Idarubicin
|
DCREPHS
|
Idarubicin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
SCH 727965 + Lomustine
|
DCJFFUH
|
Lomustine
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + Bortezomib
|
DCB0I7O
|
Bortezomib
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
SCH 727965 + Bortezomib
|
DCS27DN
|
Bortezomib
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
SCH 727965 + Bortezomib
|
DCW3TTW
|
Bortezomib
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + Bortezomib
|
DC0ZVQG
|
Bortezomib
|
Carcinoma (Cell Line: OV90)
|
[4] |
|
SCH 727965 + Bortezomib
|
DCBK9UI
|
Bortezomib
|
Carcinoma (Cell Line: EFM192B)
|
[4] |
|
SCH 727965 + Bortezomib
|
DCSAP4Q
|
Bortezomib
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
SCH 727965 + Bortezomib
|
DCQVGPL
|
Bortezomib
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
SCH 727965 + Bortezomib
|
DCTATCF
|
Bortezomib
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
SCH 727965 + Bortezomib
|
DCI1YZ7
|
Bortezomib
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[4] |
|
SCH 727965 + Valrubicin
|
DCKVWFQ
|
Valrubicin
|
Carcinoma (Cell Line: RXF 393)
|
[4] |
|
SCH 727965 + Valrubicin
|
DCTBWQQ
|
Valrubicin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
SCH 727965 + Valrubicin
|
DC6A5AC
|
Valrubicin
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
SCH 727965 + Valrubicin
|
DCZTHPL
|
Valrubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
SCH 727965 + GSK525762
|
DCCPGB4
|
GSK525762
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[4] |
|
SCH 727965 + GSK525762
|
DC4ADUK
|
GSK525762
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
SCH 727965 + GSK525762
|
DC5JBBF
|
GSK525762
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + GSK525762
|
DCQCSBE
|
GSK525762
|
Carcinoma (Cell Line: OV90)
|
[4] |
|
SCH 727965 + GSK525762
|
DCD3N8V
|
GSK525762
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
SCH 727965 + GSK525762
|
DCRQZ86
|
GSK525762
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
SCH 727965 + Sorafenib
|
DCAHTA9
|
Sorafenib
|
Breast carcinoma (Cell Line: ZR751)
|
[4] |
|
SCH 727965 + Sorafenib
|
DCPBXNU
|
Sorafenib
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + Sorafenib
|
DCAZVHM
|
Sorafenib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
SCH 727965 + MK-2206
|
DCOH8VM
|
MK-2206
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289)
|
[4] |
|
SCH 727965 + MK-2206
|
DC7MCBZ
|
MK-2206
|
Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)
|
[4] |
|
SCH 727965 + MK-2206
|
DCWSSCS
|
MK-2206
|
Breast carcinoma (Cell Line: ZR751)
|
[4] |
|
SCH 727965 + MK-2206
|
DCPJ3OG
|
MK-2206
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
SCH 727965 + MK-2206
|
DCOHNUZ
|
MK-2206
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
SCH 727965 + MK-2206
|
DC7A2G3
|
MK-2206
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
SCH 727965 + MK-2206
|
DCTQC52
|
MK-2206
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
SCH 727965 + MK-2206
|
DCHGWUP
|
MK-2206
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
SCH 727965 + MK-2206
|
DCUUUJ6
|
MK-2206
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[4] |
|
SCH 727965 + Pomalidomide
|
DC7ZE5U
|
Pomalidomide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
SCH 727965 + Vinflunine
|
DC73KW6
|
Vinflunine
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
SCH 727965 + Vinflunine
|
DC50RVI
|
Vinflunine
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
SCH 727965 + PMID28870136-Compound-43
|
DCHOQ4Q
|
PMID28870136-Compound-43
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
SCH 727965 + Vorinostat
|
DCKPV1A
|
Vorinostat
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
SCH 727965 + Vorinostat
|
DCCANFM
|
Vorinostat
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
SCH 727965 + Dasatinib
|
DCTJGVG
|
Dasatinib
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
SCH 727965 + Dasatinib
|
DC8OJYT
|
Dasatinib
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
SCH 727965 + Dasatinib
|
DCX1IW7
|
Dasatinib
|
Carcinoma (Cell Line: EFM192B)
|
[4] |
|
SCH 727965 + Dasatinib
|
DC4PD8L
|
Dasatinib
|
Carcinoma (Cell Line: MDAMB436)
|
[4] |
|
SCH 727965 + Dasatinib
|
DCIUMCB
|
Dasatinib
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
SCH 727965 + Dasatinib
|
DCK6RS5
|
Dasatinib
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
SCH 727965 + Dasatinib
|
DC69RU9
|
Dasatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
SCH 727965 + Dasatinib
|
DCO26VC
|
Dasatinib
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[4] |
|
SCH 727965 + Pentostatin
|
DCBF9MY
|
Pentostatin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
SCH 727965 + Fulvestrant
|
DCMK4D7
|
Fulvestrant
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
SCH 727965 + Fulvestrant
|
DCH5W2A
|
Fulvestrant
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
SCH 727965 + Fulvestrant
|
DC2CA14
|
Fulvestrant
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
SCH 727965 + PD-0325901
|
DC8MVO1
|
PD-0325901
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCUKRQG
|
PD-0325901
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
SCH 727965 + PD-0325901
|
DC3QC57
|
PD-0325901
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCE4M13
|
PD-0325901
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCQ41XZ
|
PD-0325901
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCEXRB4
|
PD-0325901
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCJ4RB5
|
PD-0325901
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCQAE80
|
PD-0325901
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCFJOD3
|
PD-0325901
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCA0Z42
|
PD-0325901
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + PD-0325901
|
DC3HLFN
|
PD-0325901
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + PD-0325901
|
DC9NLCP
|
PD-0325901
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCZYOQU
|
PD-0325901
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + PD-0325901
|
DC5DGWE
|
PD-0325901
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCJ0NVY
|
PD-0325901
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + PD-0325901
|
DC1LSTR
|
PD-0325901
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + PD-0325901
|
DC8GWJW
|
PD-0325901
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCFHDAU
|
PD-0325901
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCOF3G0
|
PD-0325901
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCLHZK0
|
PD-0325901
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCZHNC1
|
PD-0325901
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
SCH 727965 + PD-0325901
|
DCU9Q32
|
PD-0325901
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + Ixabepilone
|
DCIS5WG
|
Ixabepilone
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
SCH 727965 + Ixabepilone
|
DC9M9GB
|
Ixabepilone
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
SCH 727965 + Ixabepilone
|
DC949DQ
|
Ixabepilone
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
SCH 727965 + Ixabepilone
|
DCFLRLC
|
Ixabepilone
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
SCH 727965 + Ixabepilone
|
DCXWXCM
|
Ixabepilone
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + Ixabepilone
|
DCPSNVX
|
Ixabepilone
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCXT9GC
|
Lapatinib
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCRBUTX
|
Lapatinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
SCH 727965 + Lapatinib
|
DC13YSB
|
Lapatinib
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCL54WA
|
Lapatinib
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCV3M1I
|
Lapatinib
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCLPPZ0
|
Lapatinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCXNBQ0
|
Lapatinib
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + Lapatinib
|
DC8NREV
|
Lapatinib
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCAXXR2
|
Lapatinib
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCQMHPI
|
Lapatinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCG6KRX
|
Lapatinib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCN9MKR
|
Lapatinib
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + Lapatinib
|
DC0F3DB
|
Lapatinib
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCGEUEJ
|
Lapatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCRN70O
|
Lapatinib
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCCR44N
|
Lapatinib
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCMRUVM
|
Lapatinib
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCBK6ZT
|
Lapatinib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCUR672
|
Lapatinib
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + Lapatinib
|
DC12UZ6
|
Lapatinib
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
SCH 727965 + Lapatinib
|
DC2CN77
|
Lapatinib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + Lapatinib
|
DCMEIY5
|
Lapatinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
SCH 727965 + Lapatinib
|
DC02XQC
|
Lapatinib
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + MK-1775
|
DCTHQ0O
|
MK-1775
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + MK-1775
|
DCRTG0L
|
MK-1775
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
SCH 727965 + MK-1775
|
DCKN2J6
|
MK-1775
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
SCH 727965 + MK-1775
|
DCV83HO
|
MK-1775
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + MK-1775
|
DCAOUYE
|
MK-1775
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + MK-1775
|
DCP2EGW
|
MK-1775
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + MK-1775
|
DCKSW32
|
MK-1775
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + MK-1775
|
DCELXAQ
|
MK-1775
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + MK-1775
|
DCELEVY
|
MK-1775
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + MK-1775
|
DC9AJ7L
|
MK-1775
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
SCH 727965 + MK-1775
|
DCQVUW2
|
MK-1775
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + MK-1775
|
DC5EHSD
|
MK-1775
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + MK-1775
|
DCN32GL
|
MK-1775
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + MK-1775
|
DC6QENA
|
MK-1775
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + Isoniazid
|
DC631BG
|
Isoniazid
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
SCH 727965 + Isoniazid
|
DC6IEOO
|
Isoniazid
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
SCH 727965 + RTB101
|
DCZPUJP
|
RTB101
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + RTB101
|
DCG8JG3
|
RTB101
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + RTB101
|
DCQGR5Z
|
RTB101
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
SCH 727965 + RTB101
|
DCKTMAI
|
RTB101
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
SCH 727965 + RTB101
|
DCKTV40
|
RTB101
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + RTB101
|
DCO4K1X
|
RTB101
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + RTB101
|
DCN0FCN
|
RTB101
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + RTB101
|
DCTTJO9
|
RTB101
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + RTB101
|
DCFPIIA
|
RTB101
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + RTB101
|
DCEGMN5
|
RTB101
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
SCH 727965 + RTB101
|
DCWCVOI
|
RTB101
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + RTB101
|
DCHBUCT
|
RTB101
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + RTB101
|
DCI057A
|
RTB101
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + RTB101
|
DC38Q9O
|
RTB101
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + RTB101
|
DCZ590L
|
RTB101
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
SCH 727965 + RTB101
|
DCLY1M6
|
RTB101
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + RTB101
|
DCBBX9G
|
RTB101
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + RTB101
|
DCHBIG2
|
RTB101
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + RTB101
|
DCDAWN4
|
RTB101
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + RTB101
|
DCB2QR9
|
RTB101
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
SCH 727965 + RTB101
|
DCYZG6H
|
RTB101
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + RTB101
|
DCNHMMU
|
RTB101
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
SCH 727965 + RTB101
|
DCH3S9D
|
RTB101
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
SCH 727965 + RTB101
|
DCRSEZH
|
RTB101
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCA6RV1
|
SCH-900776
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCO77CY
|
SCH-900776
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + SCH-900776
|
DC4V54L
|
SCH-900776
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + SCH-900776
|
DC7K0MG
|
SCH-900776
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + SCH-900776
|
DC29FJP
|
SCH-900776
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCFSSX6
|
SCH-900776
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + SCH-900776
|
DC4XTCM
|
SCH-900776
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCJL27L
|
SCH-900776
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCVDCC9
|
SCH-900776
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCMJTED
|
SCH-900776
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCV9UV4
|
SCH-900776
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCPBTAA
|
SCH-900776
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCDGA0L
|
SCH-900776
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + SCH-900776
|
DC7HJMU
|
SCH-900776
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCOXZUA
|
SCH-900776
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCMC99S
|
SCH-900776
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + SCH-900776
|
DC5VA04
|
SCH-900776
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + SCH-900776
|
DCMTY2S
|
SCH-900776
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + Plicamycin
|
DCLXN1R
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
SCH 727965 + Plicamycin
|
DC1JZD7
|
Plicamycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
SCH 727965 + Plicamycin
|
DCYONGQ
|
Plicamycin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[3] |
|
SCH 727965 + Plicamycin
|
DC7HGEQ
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
SCH 727965 + Plicamycin
|
DCRA9IY
|
Plicamycin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
SCH 727965 + Plicamycin
|
DCEGF2U
|
Plicamycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
SCH 727965 + Triapine
|
DCC47B5
|
Triapine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
SCH 727965 + Triapine
|
DC0LXEE
|
Triapine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCSEVUH
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCPB73B
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCDZPOW
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCPGCMQ
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCKD99J
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCL5PPA
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCGV8E7
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DC3P7GW
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCRJ5AZ
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCX2HO7
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCLEAIF
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCYL316
|
10-hydroxycamptothecin
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DC4S44I
|
10-hydroxycamptothecin
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DC7OTQE
|
10-hydroxycamptothecin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DC92FJ5
|
10-hydroxycamptothecin
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCH1QF2
|
10-hydroxycamptothecin
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCNH31A
|
10-hydroxycamptothecin
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCJVISE
|
10-hydroxycamptothecin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCAIQR2
|
10-hydroxycamptothecin
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCRAIJC
|
10-hydroxycamptothecin
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCCZBWU
|
10-hydroxycamptothecin
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DC5BUZQ
|
10-hydroxycamptothecin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCK8T8X
|
10-hydroxycamptothecin
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
SCH 727965 + 10-hydroxycamptothecin
|
DCJ3JPL
|
10-hydroxycamptothecin
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + Pralatrexate
|
DC1IQAG
|
Pralatrexate
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
SCH 727965 + Pralatrexate
|
DCNTZD1
|
Pralatrexate
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + Pralatrexate
|
DCM2BSB
|
Pralatrexate
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
SCH 727965 + Pralatrexate
|
DCX8F1X
|
Pralatrexate
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCVZK22
|
SNX-2112
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCEJ0I0
|
SNX-2112
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
SCH 727965 + SNX-2112
|
DC6B7J1
|
SNX-2112
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + SNX-2112
|
DC99D59
|
SNX-2112
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
SCH 727965 + SNX-2112
|
DC6EYWZ
|
SNX-2112
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + SNX-2112
|
DC3BZZM
|
SNX-2112
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCJCPPS
|
SNX-2112
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCJDRIR
|
SNX-2112
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + SNX-2112
|
DC1P9RZ
|
SNX-2112
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCSK9RL
|
SNX-2112
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCX63AB
|
SNX-2112
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCKIF96
|
SNX-2112
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCM4DWY
|
SNX-2112
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCMLM2Y
|
SNX-2112
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCRUBB6
|
SNX-2112
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCDX2E6
|
SNX-2112
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCJW0L0
|
SNX-2112
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCW9K9E
|
SNX-2112
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCFCGM5
|
SNX-2112
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCUB2MT
|
SNX-2112
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCOFKPH
|
SNX-2112
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + SNX-2112
|
DCUZS0S
|
SNX-2112
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
SCH 727965 + SNX-2112
|
DC0L9XJ
|
SNX-2112
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
SCH 727965 + SNX-2112
|
DC9EN77
|
SNX-2112
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + Terameprocol
|
DCSMN2R
|
Terameprocol
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + Terameprocol
|
DCETV9W
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
SCH 727965 + Terameprocol
|
DC3WBS1
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCBGK5Y
|
Erlotinib
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCVT3OI
|
Erlotinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCK04LM
|
Erlotinib
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCYLYV6
|
Erlotinib
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
SCH 727965 + Erlotinib
|
DC9TDN7
|
Erlotinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCVUDQ8
|
Erlotinib
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + Erlotinib
|
DC7WFAI
|
Erlotinib
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCLRN0Z
|
Erlotinib
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + Erlotinib
|
DC98ZPQ
|
Erlotinib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCX2GQ8
|
Erlotinib
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
SCH 727965 + Erlotinib
|
DC33XGD
|
Erlotinib
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCAMBJA
|
Erlotinib
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCZPDQ3
|
Erlotinib
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + Erlotinib
|
DC36TQ7
|
Erlotinib
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCHT28T
|
Erlotinib
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + Erlotinib
|
DC2RR4R
|
Erlotinib
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + Erlotinib
|
DC4J01B
|
Erlotinib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + Erlotinib
|
DC2M3XJ
|
Erlotinib
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCGASXP
|
Erlotinib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCGPPPC
|
Erlotinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCHQO4B
|
Erlotinib
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
SCH 727965 + Erlotinib
|
DCHM9M2
|
Erlotinib
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + MK-5108
|
DCPA2ZY
|
MK-5108
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + MK-5108
|
DCUW6N3
|
MK-5108
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + MK-5108
|
DCADS4G
|
MK-5108
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + MK-5108
|
DCZBWR7
|
MK-5108
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + MK-5108
|
DCUODBQ
|
MK-5108
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + MK-5108
|
DCCAV6I
|
MK-5108
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + MK-5108
|
DCCSGCB
|
MK-5108
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
SCH 727965 + MK-5108
|
DCU98CA
|
MK-5108
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + MK-5108
|
DCNSBDH
|
MK-5108
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + MK-5108
|
DCN7XPG
|
MK-5108
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + MK-5108
|
DCYT7CV
|
MK-5108
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + MK-5108
|
DCH18AH
|
MK-5108
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + MK-5108
|
DCVW1WR
|
MK-5108
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + MK-5108
|
DC6TFTC
|
MK-5108
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + MK-5108
|
DC6VI1Z
|
MK-5108
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
SCH 727965 + Mitomycin
|
DC4XGZM
|
Mitomycin
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
SCH 727965 + Mitomycin
|
DC439XI
|
Mitomycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
SCH 727965 + Altretamine
|
DCHWNMB
|
Altretamine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
SCH 727965 + Altretamine
|
DC0UNBB
|
Altretamine
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCDEMPY
|
Ridaforolimus
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCMTW0E
|
Ridaforolimus
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCIKHF6
|
Ridaforolimus
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCMK9Y9
|
Ridaforolimus
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCP8IOP
|
Ridaforolimus
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCYFQOS
|
Ridaforolimus
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DC9K291
|
Ridaforolimus
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCZTKNF
|
Ridaforolimus
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCHJI10
|
Ridaforolimus
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DC60NVT
|
Ridaforolimus
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCCFMW0
|
Ridaforolimus
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCAPBAE
|
Ridaforolimus
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCRS76M
|
Ridaforolimus
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DC916VH
|
Ridaforolimus
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCXCA3V
|
Ridaforolimus
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DC6WQ7G
|
Ridaforolimus
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DC0RRZX
|
Ridaforolimus
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCJMWA6
|
Ridaforolimus
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DCPXSYD
|
Ridaforolimus
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
SCH 727965 + Ridaforolimus
|
DC3DXJR
|
Ridaforolimus
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + TEM
|
DCEYVAK
|
TEM
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
SCH 727965 + TEM
|
DCS8LO1
|
TEM
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
SCH 727965 + MK-4827
|
DC696X1
|
MK-4827
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + MK-4827
|
DC1DDQ1
|
MK-4827
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
SCH 727965 + MK-4827
|
DCHTTY5
|
MK-4827
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + MK-4827
|
DCLPMDM
|
MK-4827
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
SCH 727965 + MK-4827
|
DCD6ULY
|
MK-4827
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
SCH 727965 + MK-4827
|
DCQ97H9
|
MK-4827
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + MK-4827
|
DCNYKAI
|
MK-4827
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + MK-4827
|
DCNDJ48
|
MK-4827
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + MK-4827
|
DC4LTRP
|
MK-4827
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + MK-4827
|
DCGV3UZ
|
MK-4827
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + MK-4827
|
DC82UBL
|
MK-4827
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
SCH 727965 + MK-4827
|
DC9ZVQB
|
MK-4827
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + MK-4827
|
DC9GIIF
|
MK-4827
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + MK-4827
|
DC61CRJ
|
MK-4827
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + MK-4827
|
DCBOLHQ
|
MK-4827
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + MK-4827
|
DCQBEQC
|
MK-4827
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
SCH 727965 + MK-4827
|
DCZ1MPD
|
MK-4827
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + MK-4827
|
DCO3GRW
|
MK-4827
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + MK-4827
|
DC2DTRI
|
MK-4827
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + MK-4827
|
DCEFV8W
|
MK-4827
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + MK-4827
|
DC7XKKZ
|
MK-4827
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
SCH 727965 + MK-4827
|
DC8ODSZ
|
MK-4827
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + MK-4827
|
DCPQ91K
|
MK-4827
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
SCH 727965 + MK-4827
|
DC0U3H4
|
MK-4827
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
SCH 727965 + MK-4827
|
DCSWNY4
|
MK-4827
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + Idarubicin
|
DCNFQCE
|
Idarubicin
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + Idarubicin
|
DC0F6BE
|
Idarubicin
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
SCH 727965 + Idarubicin
|
DC6050G
|
Idarubicin
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + Idarubicin
|
DCIL0Q7
|
Idarubicin
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + Idarubicin
|
DCUMWSL
|
Idarubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + Idarubicin
|
DCMS3G1
|
Idarubicin
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + Idarubicin
|
DCDNCMR
|
Idarubicin
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + Idarubicin
|
DCNW4H8
|
Idarubicin
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + Lomustine
|
DCSWLF6
|
Lomustine
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
SCH 727965 + Lomustine
|
DCDEF6R
|
Lomustine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + Lomustine
|
DCS1LNE
|
Lomustine
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + Lomustine
|
DC33CRL
|
Lomustine
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + Lomustine
|
DCTL9GX
|
Lomustine
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
SCH 727965 + Lomustine
|
DCFX1NM
|
Lomustine
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + Bleomycin
|
DCPVDEH
|
Bleomycin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
SCH 727965 + Bortezomib
|
DCAPM1C
|
Bortezomib
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + Bortezomib
|
DCLFJL7
|
Bortezomib
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + Bortezomib
|
DCF5CU4
|
Bortezomib
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + Bortezomib
|
DCDJ1T7
|
Bortezomib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + Bortezomib
|
DCEPJYA
|
Bortezomib
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
SCH 727965 + Bortezomib
|
DCXNNM6
|
Bortezomib
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + Bortezomib
|
DC5OS2F
|
Bortezomib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + Bortezomib
|
DC7D6B0
|
Bortezomib
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + Bortezomib
|
DCTCMHB
|
Bortezomib
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + Bortezomib
|
DCLM3CF
|
Bortezomib
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + Bortezomib
|
DCL0SP1
|
Bortezomib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + Bortezomib
|
DCCER6X
|
Bortezomib
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + Bortezomib
|
DC513GB
|
Bortezomib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + Bortezomib
|
DCW6RCC
|
Bortezomib
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
SCH 727965 + Bortezomib
|
DC7BSAB
|
Bortezomib
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + Valrubicin
|
DC5MKNF
|
Valrubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
SCH 727965 + Valrubicin
|
DC2HNV6
|
Valrubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCKBY92
|
Valrubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCYOP9S
|
Valrubicin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCW2NC9
|
Valrubicin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCR7ES1
|
Valrubicin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + Valrubicin
|
DC6U5RO
|
Valrubicin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCDTD20
|
Valrubicin
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCCO3KL
|
Valrubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
SCH 727965 + Valrubicin
|
DC4B7EZ
|
Valrubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCEMDPV
|
Valrubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCXET5M
|
Valrubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCL0QJR
|
Valrubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCJ9X6E
|
Valrubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCKIRZX
|
Valrubicin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCRAVKK
|
Valrubicin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
SCH 727965 + Valrubicin
|
DC58857
|
Valrubicin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCK864R
|
Valrubicin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCVR6RL
|
Valrubicin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCNGAI7
|
Valrubicin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
SCH 727965 + Valrubicin
|
DCI6KVJ
|
Valrubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
SCH 727965 + GSK525762
|
DC5DZDR
|
GSK525762
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
SCH 727965 + GSK525762
|
DC23MYV
|
GSK525762
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + GSK525762
|
DCOO6US
|
GSK525762
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + GSK525762
|
DCR9QWK
|
GSK525762
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + Cisplatin
|
DC1R0WB
|
Cisplatin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
SCH 727965 + Chlorambucil
|
DC3NOJS
|
Chlorambucil
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
SCH 727965 + Chlorambucil
|
DCWFX3A
|
Chlorambucil
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
SCH 727965 + Sorafenib
|
DCDY5MC
|
Sorafenib
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + Sorafenib
|
DC3SELN
|
Sorafenib
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + Sorafenib
|
DCQ8OZP
|
Sorafenib
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + Sorafenib
|
DCMLQA1
|
Sorafenib
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + Sorafenib
|
DCXGQEA
|
Sorafenib
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + Sorafenib
|
DCT4IYJ
|
Sorafenib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + Sorafenib
|
DCHE3LF
|
Sorafenib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
SCH 727965 + Sorafenib
|
DC0O79H
|
Sorafenib
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + Sorafenib
|
DCOD5RV
|
Sorafenib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
SCH 727965 + Sorafenib
|
DCW6IVX
|
Sorafenib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + Sorafenib
|
DCHPOEW
|
Sorafenib
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + Sorafenib
|
DCZ4VSS
|
Sorafenib
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
SCH 727965 + Sorafenib
|
DCW6K0Q
|
Sorafenib
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + Sorafenib
|
DCMSKLL
|
Sorafenib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + Sorafenib
|
DC1OGA1
|
Sorafenib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + ER819762
|
DC0OQ7U
|
ER819762
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
SCH 727965 + MK-2206
|
DCNPW8U
|
MK-2206
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + MK-2206
|
DC56YTG
|
MK-2206
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + MK-2206
|
DCUGO62
|
MK-2206
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
SCH 727965 + MK-2206
|
DCYDBUS
|
MK-2206
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
SCH 727965 + MK-2206
|
DC6AW92
|
MK-2206
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
SCH 727965 + MK-2206
|
DCDSZ42
|
MK-2206
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + MK-2206
|
DCL6JWO
|
MK-2206
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + MK-2206
|
DCQ6LRR
|
MK-2206
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + MK-2206
|
DCD42TG
|
MK-2206
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + MK-2206
|
DCT14BL
|
MK-2206
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + MK-2206
|
DCCNI9P
|
MK-2206
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + MK-2206
|
DCC43XJ
|
MK-2206
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + MK-2206
|
DCJUW32
|
MK-2206
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + MK-2206
|
DC7OC4J
|
MK-2206
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + MK-2206
|
DCI3ME4
|
MK-2206
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
SCH 727965 + MK-2206
|
DCJK4ZK
|
MK-2206
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + MK-2206
|
DCLOREQ
|
MK-2206
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + MK-2206
|
DCHU4T8
|
MK-2206
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + MK-2206
|
DCCVKHI
|
MK-2206
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + MK-2206
|
DCRZ595
|
MK-2206
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
SCH 727965 + MK-2206
|
DCVV6L2
|
MK-2206
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + MK-2206
|
DCUEBAO
|
MK-2206
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
SCH 727965 + MK-2206
|
DCK5AQU
|
MK-2206
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
SCH 727965 + MK-2206
|
DCELEML
|
MK-2206
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + Pomalidomide
|
DC7QV99
|
Pomalidomide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
SCH 727965 + Pomalidomide
|
DCLUVUO
|
Pomalidomide
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
SCH 727965 + Vinflunine
|
DCE0ZJ3
|
Vinflunine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
SCH 727965 + Vinflunine
|
DCLBITW
|
Vinflunine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
SCH 727965 + Vinflunine
|
DCD3313
|
Vinflunine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
SCH 727965 + Vinflunine
|
DC9ISN2
|
Vinflunine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
SCH 727965 + Mercaptopurine
|
DCC66B5
|
Mercaptopurine
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
SCH 727965 + Mepacrine
|
DC3OZ62
|
Mepacrine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
SCH 727965 + PMID28870136-Compound-43
|
DC1JR95
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
SCH 727965 + PMID28870136-Compound-43
|
DC4MNJ9
|
PMID28870136-Compound-43
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
SCH 727965 + PMID28870136-Compound-43
|
DCRDV2Q
|
PMID28870136-Compound-43
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
SCH 727965 + FORMESTANE
|
DCB9XNJ
|
FORMESTANE
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
SCH 727965 + FORMESTANE
|
DC61U85
|
FORMESTANE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
SCH 727965 + FORMESTANE
|
DC4TL3L
|
FORMESTANE
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
SCH 727965 + Vorinostat
|
DC1P1GU
|
Vorinostat
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
SCH 727965 + Vorinostat
|
DC8AQD0
|
Vorinostat
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + Vorinostat
|
DCN5SZD
|
Vorinostat
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
SCH 727965 + Vorinostat
|
DCF60S1
|
Vorinostat
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + Vorinostat
|
DCTW5RS
|
Vorinostat
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + Vorinostat
|
DCAE0XS
|
Vorinostat
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + Vorinostat
|
DCQGCWH
|
Vorinostat
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
SCH 727965 + Vorinostat
|
DC7PHE7
|
Vorinostat
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + Vorinostat
|
DCU12K2
|
Vorinostat
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + Vorinostat
|
DC26REZ
|
Vorinostat
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + Vorinostat
|
DCCPEB2
|
Vorinostat
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + Vorinostat
|
DC3EFXI
|
Vorinostat
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
SCH 727965 + Vorinostat
|
DCPXP0A
|
Vorinostat
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + Vorinostat
|
DCTA3FY
|
Vorinostat
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + Vorinostat
|
DCK2PVR
|
Vorinostat
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
SCH 727965 + Aminolevulinic Acid Hydrochloride
|
DC97O66
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + Aminolevulinic Acid Hydrochloride
|
DCUMC3M
|
Aminolevulinic Acid Hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + Aminolevulinic Acid Hydrochloride
|
DCEW2EM
|
Aminolevulinic Acid Hydrochloride
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
SCH 727965 + Aminolevulinic Acid Hydrochloride
|
DCK2BTG
|
Aminolevulinic Acid Hydrochloride
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
SCH 727965 + Busulfan
|
DCOHUCK
|
Busulfan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCIMAN2
|
Dasatinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCO32AL
|
Dasatinib
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCA99WV
|
Dasatinib
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCFWLRV
|
Dasatinib
|
Adenocarcinoma (Cell Line: NCIH2122)
|
[3] |
|
SCH 727965 + Dasatinib
|
DC8HPTY
|
Dasatinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
SCH 727965 + Dasatinib
|
DC34TGX
|
Dasatinib
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
SCH 727965 + Dasatinib
|
DC4W22K
|
Dasatinib
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCBUGNW
|
Dasatinib
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
SCH 727965 + Dasatinib
|
DC8RO0I
|
Dasatinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCDD10G
|
Dasatinib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCESF18
|
Dasatinib
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCT8Q1V
|
Dasatinib
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCG06CM
|
Dasatinib
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
SCH 727965 + Dasatinib
|
DC92V6B
|
Dasatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCU3RBR
|
Dasatinib
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCNLO3Y
|
Dasatinib
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCC56V2
|
Dasatinib
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
SCH 727965 + Dasatinib
|
DC2AJ5Q
|
Dasatinib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCS2U0L
|
Dasatinib
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCHH4ZL
|
Dasatinib
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCL76KL
|
Dasatinib
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCO223Y
|
Dasatinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
SCH 727965 + Dasatinib
|
DCKW865
|
Dasatinib
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
SCH 727965 + Dasatinib
|
DC36GW4
|
Dasatinib
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
Sirolimus + SCH 727965
|
DCBTP44
|
Sirolimus
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Sirolimus + SCH 727965
|
DCRWP21
|
Sirolimus
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Sirolimus + SCH 727965
|
DC1VM81
|
Sirolimus
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Steroid derivative 1 + SCH 727965
|
DCGM5BR
|
Steroid derivative 1
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
Sumatriptan + SCH 727965
|
DCA4INZ
|
Sumatriptan
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
SY-1425 + SCH 727965
|
DCEN33R
|
SY-1425
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
SY-1425 + SCH 727965
|
DC97LFY
|
SY-1425
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
SY-1425 + SCH 727965
|
DC8XE4Z
|
SY-1425
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Taxol + SCH 727965
|
DC8CYQJ
|
Taxol
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Taxol + SCH 727965
|
DCZSJPL
|
Taxol
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Taxol + SCH 727965
|
DCDGE1S
|
Taxol
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Taxol + SCH 727965
|
DC4ICDI
|
Taxol
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Taxol + SCH 727965
|
DCJQ765
|
Taxol
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Taxol + SCH 727965
|
DC5WLVV
|
Taxol
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[2] |
|
Taxol + SCH 727965
|
DCRLJPR
|
Taxol
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Taxol + SCH 727965
|
DCD02A3
|
Taxol
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Taxol + SCH 727965
|
DCYKUK5
|
Taxol
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Taxol + SCH 727965
|
DCKU2O8
|
Taxol
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Taxol + SCH 727965
|
DC3X79A
|
Taxol
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Taxol + SCH 727965
|
DCX9VG3
|
Taxol
|
Colon carcinoma (Cell Line: KM12)
|
[4] |
|
Taxol + SCH 727965
|
DCBVHW3
|
Taxol
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[4] |
|
Taxol + SCH 727965
|
DCTF34Y
|
Taxol
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[4] |
|
Taxol + SCH 727965
|
DCRX4P6
|
Taxol
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Taxol + SCH 727965
|
DC179M2
|
Taxol
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
Taxol + SCH 727965
|
DC7V25M
|
Taxol
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Taxol + SCH 727965
|
DC0QVLQ
|
Taxol
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Taxol + SCH 727965
|
DCYJW5I
|
Taxol
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Taxol + SCH 727965
|
DCYJXV5
|
Taxol
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Taxol + SCH 727965
|
DC3W6XM
|
Taxol
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Taxol + SCH 727965
|
DC896L4
|
Taxol
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Taxol + SCH 727965
|
DCS1NLX
|
Taxol
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Taxol + SCH 727965
|
DC96IE4
|
Taxol
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Taxol + SCH 727965
|
DCIIFVL
|
Taxol
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Taxol + SCH 727965
|
DCY64R5
|
Taxol
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Taxol + SCH 727965
|
DC5M15X
|
Taxol
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Taxol + SCH 727965
|
DCO0H3K
|
Taxol
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Taxol + SCH 727965
|
DCOOBWK
|
Taxol
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Taxol + SCH 727965
|
DCOC51Q
|
Taxol
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Taxol + SCH 727965
|
DCPXMIP
|
Taxol
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Taxol + SCH 727965
|
DC4IGH4
|
Taxol
|
Mesothelioma (Cell Line: MSTO)
|
[3] |
|
Taxol + SCH 727965
|
DC7G4M2
|
Taxol
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Taxol + SCH 727965
|
DCELY2Y
|
Taxol
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Taxol + SCH 727965
|
DCVKKNJ
|
Taxol
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Taxol + SCH 727965
|
DCXD9BX
|
Taxol
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Teriflunomide + SCH 727965
|
DCCX49J
|
Teriflunomide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
TG100801 + SCH 727965
|
DC7IBCZ
|
TG100801
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
Thioguanine + SCH 727965
|
DCPH6YF
|
Thioguanine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Thioguanine + SCH 727965
|
DCKITK8
|
Thioguanine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Thioguanine + SCH 727965
|
DCPIJ2G
|
Thioguanine
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Thioguanine + SCH 727965
|
DCDHWEJ
|
Thioguanine
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Thioguanine + SCH 727965
|
DC8LGXH
|
Thioguanine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Thioguanine + SCH 727965
|
DCY47EG
|
Thioguanine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Thioguanine + SCH 727965
|
DCW6I6D
|
Thioguanine
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Thioguanine + SCH 727965
|
DCQJ74A
|
Thioguanine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Thioguanine + SCH 727965
|
DCLV9NP
|
Thioguanine
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Thioguanine + SCH 727965
|
DCHA01T
|
Thioguanine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Thioguanine + SCH 727965
|
DCODLS4
|
Thioguanine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Topotecan + SCH 727965
|
DCYQDCC
|
Topotecan
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
Topotecan + SCH 727965
|
DC6TAOE
|
Topotecan
|
Carcinoma (Cell Line: OV90)
|
[4] |
|
Topotecan + SCH 727965
|
DCLKC97
|
Topotecan
|
Carcinoma (Cell Line: EFM192B)
|
[4] |
|
Topotecan + SCH 727965
|
DCJZP37
|
Topotecan
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Topotecan + SCH 727965
|
DCBG3SN
|
Topotecan
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
Topotecan + SCH 727965
|
DCIRBI7
|
Topotecan
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
Topotecan + SCH 727965
|
DCMXFXM
|
Topotecan
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Topotecan + SCH 727965
|
DC2ZJGT
|
Topotecan
|
Adenocarcinoma (Cell Line: CAOV3)
|
[3] |
|
Topotecan + SCH 727965
|
DCO87VX
|
Topotecan
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
Topotecan + SCH 727965
|
DCAHS37
|
Topotecan
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Topotecan + SCH 727965
|
DCF61JD
|
Topotecan
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Topotecan + SCH 727965
|
DCX5CN2
|
Topotecan
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Topotecan + SCH 727965
|
DCJZT3L
|
Topotecan
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Topotecan + SCH 727965
|
DC7K6DG
|
Topotecan
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
Topotecan + SCH 727965
|
DCY7CXC
|
Topotecan
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Topotecan + SCH 727965
|
DCBMX96
|
Topotecan
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Topotecan + SCH 727965
|
DCRS6XV
|
Topotecan
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Topotecan + SCH 727965
|
DCBOX84
|
Topotecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Topotecan + SCH 727965
|
DCQQV9Z
|
Topotecan
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Topotecan + SCH 727965
|
DCLLM87
|
Topotecan
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Topotecan + SCH 727965
|
DCXH2F4
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Topotecan + SCH 727965
|
DC5NJGZ
|
Topotecan
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[3] |
|
Topotecan + SCH 727965
|
DC8MIMB
|
Topotecan
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Topotecan + SCH 727965
|
DC7ASKH
|
Topotecan
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Topotecan + SCH 727965
|
DC1KS14
|
Topotecan
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Topotecan + SCH 727965
|
DCOCEWI
|
Topotecan
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Topotecan + SCH 727965
|
DCH5G31
|
Topotecan
|
Malignant melanoma (Cell Line: HT144)
|
[3] |
|
Topotecan + SCH 727965
|
DCGG4XI
|
Topotecan
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Topotecan + SCH 727965
|
DCV2M07
|
Topotecan
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Topotecan + SCH 727965
|
DCY69IC
|
Topotecan
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Topotecan + SCH 727965
|
DC5PDRH
|
Topotecan
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Topotecan + SCH 727965
|
DC5VN9Q
|
Topotecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Topotecan + SCH 727965
|
DC26JD8
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Topotecan + SCH 727965
|
DCQ4J2E
|
Topotecan
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Topotecan + SCH 727965
|
DCSKVHN
|
Topotecan
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Topotecan + SCH 727965
|
DCP944H
|
Topotecan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Topotecan + SCH 727965
|
DCVC1DL
|
Topotecan
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Topotecan + SCH 727965
|
DCPXDTD
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Topotecan + SCH 727965
|
DCELSAL
|
Topotecan
|
Prostate carcinoma (Cell Line: VCAP)
|
[3] |
|
Topotecan + SCH 727965
|
DC85ZZJ
|
Topotecan
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Trifluoperazine + SCH 727965
|
DCITX4X
|
Trifluoperazine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Trifluridine + SCH 727965
|
DC7BLDV
|
Trifluridine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Trifluridine + SCH 727965
|
DCZZPXZ
|
Trifluridine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Trifluridine + SCH 727965
|
DCVI7EK
|
Trifluridine
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Trifluridine + SCH 727965
|
DC9E70U
|
Trifluridine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Trifluridine + SCH 727965
|
DCH6AF7
|
Trifluridine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Trifluridine + SCH 727965
|
DCARRL4
|
Trifluridine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Uracil mustard + SCH 727965
|
DC3C5E3
|
Uracil mustard
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vandetanib + SCH 727965
|
DC526L0
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[4] |
|
Vandetanib + SCH 727965
|
DC8VZ9E
|
Vandetanib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + SCH 727965
|
DCSL93U
|
Vemurafenib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[4] |
|
Vemurafenib + SCH 727965
|
DCUHWNK
|
Vemurafenib
|
Carcinoma (Cell Line: MCF7)
|
[4] |
|
Vemurafenib + SCH 727965
|
DCNPUVY
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vemurafenib + SCH 727965
|
DCT012Z
|
Vemurafenib
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vemurafenib + SCH 727965
|
DCAP27Y
|
Vemurafenib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Vemurafenib + SCH 727965
|
DC6L973
|
Vemurafenib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vemurafenib + SCH 727965
|
DC2K4HS
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + SCH 727965
|
DCEMB2P
|
Vemurafenib
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + SCH 727965
|
DC71HE3
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + SCH 727965
|
DCYO5TT
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Vemurafenib + SCH 727965
|
DC1A7LL
|
Vemurafenib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + SCH 727965
|
DCA3ZM0
|
Vemurafenib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Verteporfin + SCH 727965
|
DCBTXWV
|
Verteporfin
|
Ewing sarcoma (Cell Line: TC-71)
|
[2] |
|
Vinblastine + SCH 727965
|
DCOZYC7
|
Vinblastine
|
Adenocarcinoma (Cell Line: CAOV3)
|
[2] |
|
Vinblastine + SCH 727965
|
DC6V513
|
Vinblastine
|
Adenocarcinoma (Cell Line: A427)
|
[2] |
|
Vinblastine + SCH 727965
|
DC1ZNLD
|
Vinblastine
|
Adenocarcinoma (Cell Line: NCIH1650)
|
[2] |
|
Vinblastine + SCH 727965
|
DCNGBKB
|
Vinblastine
|
Adenocarcinoma (Cell Line: NCIH520)
|
[2] |
|
Vinblastine + SCH 727965
|
DCB7TCX
|
Vinblastine
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[2] |
|
Vinblastine + SCH 727965
|
DCYQ565
|
Vinblastine
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
Vinblastine + SCH 727965
|
DC09DPF
|
Vinblastine
|
Adenocarcinoma (Cell Line: SW-620)
|
[2] |
|
Vinblastine + SCH 727965
|
DCUPWGZ
|
Vinblastine
|
Amelanotic melanoma (Cell Line: A2058)
|
[2] |
|
Vinblastine + SCH 727965
|
DCTKDC7
|
Vinblastine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Vinblastine + SCH 727965
|
DCHQ6F6
|
Vinblastine
|
Germ cell tumour (Cell Line: PA1)
|
[2] |
|
Vinblastine + SCH 727965
|
DCZ30TQ
|
Vinblastine
|
Malignant melanoma (Cell Line: A375)
|
[2] |
|
Vinblastine + SCH 727965
|
DCMR7ON
|
Vinblastine
|
Malignant melanoma (Cell Line: HT144)
|
[2] |
|
Vinblastine + SCH 727965
|
DCWQJJW
|
Vinblastine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[2] |
|
Vinblastine + SCH 727965
|
DCMKYGK
|
Vinblastine
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Vinblastine + SCH 727965
|
DCK7232
|
Vinblastine
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[2] |
|
Vinblastine + SCH 727965
|
DC1UWIK
|
Vinblastine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
Vinblastine + SCH 727965
|
DCRN7PM
|
Vinblastine
|
Breast carcinoma (Cell Line: KPL1)
|
[4] |
|
Vinblastine + SCH 727965
|
DC14IKY
|
Vinblastine
|
Breast carcinoma (Cell Line: OCUBM)
|
[4] |
|
Vinblastine + SCH 727965
|
DC1RG4A
|
Vinblastine
|
Colon carcinoma (Cell Line: RKO)
|
[4] |
|
Vinblastine + SCH 727965
|
DCAK97G
|
Vinblastine
|
Rectal adenocarcinoma (Cell Line: SW837)
|
[4] |
|
Vincristine + SCH 727965
|
DCRHYS0
|
Vincristine
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Vincristine + SCH 727965
|
DC8VKYN
|
Vincristine
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Vincristine + SCH 727965
|
DCX1KBN
|
Vincristine
|
Adenocarcinoma (Cell Line: SW-620)
|
[2] |
|
Vincristine + SCH 727965
|
DCT67TD
|
Vincristine
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
Vincristine + SCH 727965
|
DCDMNLJ
|
Vincristine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Vincristine + SCH 727965
|
DCFHPS8
|
Vincristine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Vincristine + SCH 727965
|
DC8W0W6
|
Vincristine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Vincristine + SCH 727965
|
DCQ8VNF
|
Vincristine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[2] |
|
Vincristine + SCH 727965
|
DCW6MGX
|
Vincristine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[2] |
|
Vincristine + SCH 727965
|
DC9DARY
|
Vincristine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[2] |
|
Vincristine + SCH 727965
|
DC500M2
|
Vincristine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
Vincristine + SCH 727965
|
DCJFCXB
|
Vincristine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
Vincristine + SCH 727965
|
DCP09B4
|
Vincristine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[2] |
|
Vincristine + SCH 727965
|
DCCRP1I
|
Vincristine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Vincristine + SCH 727965
|
DCWATS7
|
Vincristine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[4] |
|
Vincristine + SCH 727965
|
DC23Z3M
|
Vincristine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[4] |
|
Vinorelbine + SCH 727965
|
DC0O6X1
|
Vinorelbine
|
Colon adenocarcinoma (Cell Line: LOVO)
|
[4] |
|
Vinorelbine + SCH 727965
|
DCCMQQZ
|
Vinorelbine
|
Adenocarcinoma (Cell Line: A427)
|
[3] |
|
Vinorelbine + SCH 727965
|
DCNBJRW
|
Vinorelbine
|
Adenocarcinoma (Cell Line: NCIH520)
|
[3] |
|
Vinorelbine + SCH 727965
|
DCCUNL4
|
Vinorelbine
|
Adenocarcinoma (Cell Line: COLO320DM)
|
[3] |
|
Vinorelbine + SCH 727965
|
DCBEWOB
|
Vinorelbine
|
Adenocarcinoma (Cell Line: DLD1)
|
[3] |
|
Vinorelbine + SCH 727965
|
DCOW3J3
|
Vinorelbine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vinorelbine + SCH 727965
|
DCRSOJG
|
Vinorelbine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vinorelbine + SCH 727965
|
DC4LVEK
|
Vinorelbine
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Vinorelbine + SCH 727965
|
DCBCKZS
|
Vinorelbine
|
Amelanotic melanoma (Cell Line: A2058)
|
[3] |
|
Vinorelbine + SCH 727965
|
DC714VI
|
Vinorelbine
|
Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)
|
[3] |
|
Vinorelbine + SCH 727965
|
DC0QSSE
|
Vinorelbine
|
Germ cell tumour (Cell Line: PA1)
|
[3] |
|
Vinorelbine + SCH 727965
|
DCGLC5I
|
Vinorelbine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vinorelbine + SCH 727965
|
DCY8VA3
|
Vinorelbine
|
Malignant melanoma (Cell Line: A375)
|
[3] |
|
Vinorelbine + SCH 727965
|
DCY06NZ
|
Vinorelbine
|
Malignant melanoma (Cell Line: RPMI7951)
|
[3] |
|
Vinorelbine + SCH 727965
|
DCIPEG6
|
Vinorelbine
|
Malignant melanoma (Cell Line: SKMEL30)
|
[3] |
|
Vinorelbine + SCH 727965
|
DC8252D
|
Vinorelbine
|
Non small cell carcinoma (Cell Line: SKMES1)
|
[3] |
|
Vinorelbine + SCH 727965
|
DCJ5M0G
|
Vinorelbine
|
Ovarian endometrioid adenocarcinoma (Cell Line: A2780)
|
[3] |
|
Vinorelbine + SCH 727965
|
DCYZD7L
|
Vinorelbine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vinorelbine + SCH 727965
|
DCT5WTM
|
Vinorelbine
|
Prostate carcinoma (Cell Line: LNCAP)
|
[3] |
|
Vismodegib + SCH 727965
|
DCW0676
|
Vismodegib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vismodegib + SCH 727965
|
DC1OLRD
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vismodegib + SCH 727965
|
DCJDMDY
|
Vismodegib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Vismodegib + SCH 727965
|
DCI0W6P
|
Vismodegib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
